Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
M á s t e r U n i v e r s i t a r i o e n I n v s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t
E d i t i o n 2 0 1 4
P r o p o s a l
2 0 1 5
Página 1 de 4
PROJECT 1 THERAPEUTIC TARGETING OF THE SLC4A2 ANION EXCHANGER IN B‐CELL MALIGNANCIES
PROJECT 2 TRAFFIC OF MEMORY AND EFFECTOR T CELLS ACROSS LYMPHATIC ENDOTHELIAL CELLS IN CANCER: OPTIMIZING IMMUNOTHERAPY
PROJECT 3 DEVELOPMENT AND IMPLEMENTATION OF RADIOLABELLING METHODOLOGIES OF POLYMERIC BIODISTRIBUTION STUDIES
NANOPARTICLES AND SNEDDS FOR IN VIVO
PROJECT 4 APTAMERS AS A NEW PLATFORM IN CANCER IMMUNOTHERAPY
PROJECT 5 MOLECULAR BASIS OF HUNTINGTON´S DISEASE: IDENTIFYING DISRUPTED SIGNALLING AND TESTING A NEW GENE THERAPY APPROACH
PROJECT 6 CHARACTERIZATION OF AND LIVER FUNCTIONS
NAA25 KNOCK‐OUT MICE: EFFECTS ON M SCLE
PROJECT 7 INHIBITION OF THE SONIC HEDGEHOG PATHWAY AND ROLE OF THE PRIMARY CILIUM AS A FACTOR OF CLINICAL PROGNOSIS IN BRAIN TUMORS
PROJECT 8 FABRICATION AND CHARACTERIZATION OF BIOMIMETIC MIGRATION STUDIES
GELS FOR CELL
*PROJECT 9 STUDY OF COMPLEMENT ACTIVATION IN LUNG CANCER CELLS FOIDENTIFICATION OF NEW THERAPEUTIC TARGETS AND DIAGNOSTIC MARKERS
THE
*PROJECT 10 ROLE OF ENDOPLASMIC RETICULUM STRESS IN THE PATHOGENESIS OFPOLYCYSTIC LIVER DISEASES
PROJECT 11 GENE THERAPY OF INHERITED LIVER METABOLIC DISORDERS
PROJECT 12 TREATMENT OF HEPATOCELLULAR CARCINOMA BY COMBINATION OF BIOLOGICAL THERAPY AND BLOCKADE OF IMMUNOSUPPRESSION
PROJECT 13 ROLE OF LNCRNAS IN CANCER EPIGENETICS
*PROJECT 14 FUNCTIONAL CHARACTERIZATION OF ONCOGENE‐REGULATEDMECHANISMS IN KRAS‐DRIVEN CANCERS
M á s t e r U n i v e r s i t a r i o e n I n v s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t
E d i t i o n 2 0 1 4
P r o p o s a l
2 0 1 5
Página 2 de 4
PROJECT 15 ROLE OF OXIDATIVE STRESS IN THE REGULATION OF MATRIX QUANTITY AND QUALITY
EXTRACELLULAR
PROJECT 16 MECHANISMS INVOLVED IN COGNITIVE DEFICITS ASSOCIATED TO INSULIN RESISTANCE IN ALZHEIMER´S DISEASE
PROJECT 17 NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF MYOCARDIAL FIBROSIS IN HEART FAILURE PATIENTS
PROJECT 18 DISSECTING MULTIGENIC MIRNAS‐DRIVEN NETWORKS IN METASTASIS
PROJECT 19 ALPHA SYNUCLEIN‐DEPENDENT MECHANISMS OF NEURODEGENERATION.
PROJECT 20 CHARACTERIZATION OF THE HOMOLOG O LEISHMANIA MAJOR.
THE ONCOGENE PES IN
PROJECT 21 REGULATION OF XBP1 SPLICING IN RESPONSE TO RETICULUM STRESS.
ENDOPLASMIC
PROJECT 22 DEVELOPMENT OF VIRAL VECTORS ABLE TO EX RESS IMMUNOMODULATORY ANTIBODIES FOR CANCER GENE THERAPY
PROJECT 23 THE FREE FATTY ACIDS RECEPTORS AS NEW TARGETS FOR ALZHEIMER’S DISEASE THERAPIES
PROJECT 24 LNCRNAS IN DISEASE
PROJECT 25 ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS
PROJECT 26 MECHANISMS OF LIVER METASTASIS IN LUNG CANCER. ROLE GENES.
OF ID
PROJECT 27 PRODUCTION AND APPLICATION OF HIGH‐CAPACITY ADENOVIRAL VECTORS IN THE TREATMENT OF GASTROINTESTINAL CANCERS
PROJECT 28 ADVANCED THERAPEUTIC STRATEGIES FOR THE TREATMENT OF LEISHMANIOSIS, A PARASITIC NEGLECTED DISEASE: NANOTECHNOLOGY APPROACHES.
PROJECT 29 ADOPTIVE CELL TRANSFER WITH GENETICALLY‐ENGINEERED T CELLS IN CANCER TREATMENT
M á s t e r U n i v e r s i t a r i o e n I n v s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t
E d i t i o n 2 0 1 4
P r o p o s a l
2 0 1 5
Página 3 de 4
PROJECT 30 IMPLICATION OF GHRELIN ISOFORMS IN THE ONSET OF NON‐ALCOHOLIC FATTY LIVER DISEASE AND STEATOHEPATITIS ASSOCIATED TO OBESITY AND INSULIN RESISTANCE
PROJECT 31 STUDY OF THE INVOLVEMENT OF EXTRACELLULAR MATRIX REMODELLING IN ADIPOSE TISSUE IN THE DEVELOPMENT OF OBESITY AND ITS COMORBIDITIES
PROJECT 32 IMPACT OF AN INTEGRAL INTERVENTION IN NAVARRA CHILDREN WITH DIABETES RISK: STUDY OF GENETIC AND EPIGENETIC MARKERS (IGENOI)
PROJECT 33 OBESITY AND CANCER: STUDY OF THE INVOLVEMENT OF ADIPOSE TISSUE INFLAMMATION, HYPOXIA AND METHYLATION IN COLON CANCER DEVELOPMENT IN OBESE PATIENTS.
PROJECT 34 ALZHEIMER DISEASE: FROM MOLECULAR BIOLOGY TO THERAPY
PROJECT 35 ASSESSMENT OF RESTING STATE BRAIN FUNCTIONAL CONNECTIVITY IN PARKINSON'S DISEASE
PROJECT 36 HEALTH IMPLICATIONS OF STEROLS´ OXIDATION PRODUCTS AND FACTORS INVOLVED IN THEIR FORMATION
PROJECT 37 DEVELOPMENT OF A SUBCELLULAR VACCINE AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC)
PROJECT 38 REGULATION OF CAVEOLIN‐1 EXPRESSION BY MICRORNAS
PROJECT 39 REGULATION OF ADIPOSE TISSUE METABOLISM IN OBESITY, INFLAMMATION AND INSULIN RESISTANCE: EFFECTS OF SPECIALIZED PRORESOLVING LIPID MEDIATORS.
PROJECT 40 DIFFERENTIAL REGULATION OF SYNAPTIC PLASTICITY MARKERS ANDBEHAVIOUR BY HISTONE DEACETYLASE INHIBITORS
M á s t e r U n i v e r s i t a r i o e n I n v s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t
E d i t i o n 2 0 1 4
P r o p o s a l
2 0 1 5
Página 4 de 4
PROJECT 41 VALIDATION OF EPIGENETIC BIOMARKERS IN BLOOD CELLS IN RELATION TO OBESITY AND THE DIET
PROJECT 42 OXIDATIVE STRESS AND STROKE: A CASE‐CONTROL STUDY
INFLAMMATORY BIOMARKERS IN THE RISK OF
PROJECT 43 EPIGENETIC MODIFICATIONS IN OBESE PATIENTS WIITH METABOLIC SYNDROME UNDER ENERGY RESTRICTION: RESMENA PROJECT
PROJECT 44 GLUCOSE TRANSPORTER GLUT‐12: HYPOXIA ASSOCIATED TO OBESITY.
TUDY OF ITS PHYSIOLOGICAL ROLE IN
*PROJECT 45 PHYSIOLOGICAL ROLE OF THE GLUCOSE TRANSPORTER GLUT12 IN THESMALL INTESTINE
*PROJECT 46 STUDY OF BRUCELLA CENTRAL CARBON METABOLISM
*PROJECT 47 REMODELING OF BRUCELLA MEMBRANE LIPIDS
PROJECT 48 PHENOTYPIC CHARACTERIZATION OF GABAergic AND GLUTAMATERGIC NEURONS IN THE HUMAN PEDUNCULOPONTINE TEGMENT
PROJECT 49 ESTUDIO DEL MECANISMO DE ACCIÓN LEISHMANICIDA DE NUEVOS DERIVADOS SELENADOS
PROJECT 50 ESTUDIO DEL SIGNIFICADO CLÍNICO PRONÓSTICO Y PREDICTIVO DEL ESTADO DE METILACIÓN DE LA ENZIMA METIL‐GUANIL‐METIL‐TRANSFERASA (MGMT) VALORADO MEDIANTE TÉCNICA DE PIROSECUENCIACIÓN. RELACIÓN DE DICHA ALTERACIÓN CON LA MUTACIÓN DE LA ENZIMA ISOCITRATO DESHIDROGENASA (IDH)
PROJ
THER
MAL
DEPA
Labo
DIRE
Jose
This
Imm
CONT
jamc
SUM
Impr
malig
that
ablat
mast
exch
(Treg
for t
loop
M á s t e
R e s
JECT 1
RAPEUTIC
IGNANCIES
ARTAMENT/
oratory of M
CTOR
A Martinez
project is
unotherapy
TACT
climent@un
MMARY
roved unde
gnancies is
are expect
tion of the a
ter regulato
ange, induc
gs) in mice.
umor immu
of AE2 dist
e r U n i v e
e a r c h P
TARGETING
/LABORATO
Molecular On
z Climent. C
s being co
y, CIMA) an
nav.es. Tel. C
erstanding
leading to
ted to be m
anion excha
or of intra
ces a reduc
We theref
unotherapy
urbed norm
e r s i t a r i o
r o j e c t P
G OF TH
ORY
ncology, Div
IMA, Hema
onducted i
d Juan Fran
CIMA ext 10
of the c
the develo
more effect
anger AE2, a
cellular pH
ction in the
fore specula
y. Custom‐d
mal pHi regu
o e n I n v e
r o p o s a l
HE SLC4A2
vision of He
atological O
in collabor
ncisco Medi
029
ellular and
opment of
tive and les
a
H (pHi) thro
number of
ated that A
designed pe
ulation thro
e s t i g a c i
E d i t i o n
2 ANION
ematologica
ncology Div
ration with
na (Hepath
d molecula
more ratio
ss toxic. W
ough Cl‐ a
f CD4+CD25
AE2 might r
eptides bin
ough blockin
ó n B i o m
2 0 1 4 ‐ 2
EXCHANG
al Malignanc
vision.
h Drs. Jua
ology, CIMA
ar pathoge
nale therap
e previousl
nd HCO3‐
5+Foxp3+ re
epresent a
ding the th
ng Cl‐/HCO3
é d i c a
0 1 5
GER IN B
cies, CIMA.
an José La
A)
enesis of
peutic strat
ly reported
transmemb
egulatory T
potential t
hird extrace
3‐ exchange
‐CELL
asarte
B‐cell
tegies
d that
brane
T cells
target
ellular
e in
lymp
augm
Unex
(70%
myel
we p
in viv
ii) tr
num
resea
B‐cel
POSS
Only
M á s t e
R e s
phocytes, w
mented IL2
xpectedly, t
%) mature
loma, and B
plan to test
vo by i) dire
riggering T‐
bers and p
arch projec
ll malignanc
SIBILITY OF
if the stude
e r U n i v e
e a r c h P
which select
secretion;
the most a
B‐cell lym
B‐cell acute
whether a
ect targetin
‐cell mediat
potentiating
t will provi
cies.
Ph.D. (YES/
ent gets fun
e r s i t a r i o
r o j e c t P
ively led to
and ii) red
ctive peptid
mphomas, B
lymphoblas
single mole
g of tumor
ted anti‐tu
g helper a
de a proof
/NO)
nds to suppo
o e n I n v e
r o p o s a l
o i) increase
uction of T
de (p17AE2
B‐cell chro
stic leukem
ecule, p17A
B cells that
mor B‐cell
and cytotox
of principle
ort his/her
e s t i g a c i
E d i t i o n
ed prolifera
Tregs with d
2) also indu
onic lymph
mia cell lines
AE2, may ex
t are forced
responses
xic effecto
e for a pote
PhD studie
ó n B i o m
2 0 1 4 ‐ 2
tion of effe
decreased I
uced apopt
ocytic leuk
and primar
ert a dual a
d to undergo
through d
r T cells. W
ential new s
s.
é d i c a
0 1 5
ector T cell
IL10 produc
tosis in 32
kemia, mu
ry samples.
anti‐tumor e
o apoptosis
decreasing
We expect
strategy to
s and
ction.
of 46
ultiple
Here
effect
s; and
Tregs
t this
treat
PROJ
TRAF
IN CA
DEPA
Imm
DIRE
Ana
CONT
arou
SUM
Imm
main
able
cells
lymp
is co
dend
when
In th
the
malig
M á s t e
R e s
JECT 2
FFIC OF MEM
ANCER: OPT
ARTAMENT/
unotherapy
CTOR
Rouzaut
TACT
zaut@unav
MMARY
unotherapy
n restriction
to access th
use the lym
ph nodes an
onditioned b
dritic cells s
n they have
is project, f
molecular
gnant tissue
e r U n i v e
e a r c h P
MORY AND
TIMIZING IM
/LABORATO
y. CIMA.
v.es. Tel. CI
y has emer
ns of this th
he tumor st
mphatic ve
nd for recirc
by the infla
switch from
e to transit a
funded by t
mechanism
e in the con
e r s i t a r i o
r o j e c t P
EFFECTOR
MMUNOTHE
ORY
MA: 34 948
rged as a p
herapy eme
troma and d
ssels (LVs)
culation. Th
ammatory c
m an integr
across inflam
he Spanish
ms involved
ntext of imm
o e n I n v e
r o p o s a l
T CELLS AC
ERAPY.
8 194700 Ex
promising th
erge from t
draining lym
as conduits
he propensi
context; in
rin indepen
med LVs.
Ministry of
d in T cell
munotherap
e s t i g a c i
E d i t i o n
CROSS LYMP
xt 1006
herapy to f
the limited
mph nodes.
s to egress
ity of leuko
fact we ha
dent to an
f Health (FIS
l transit ac
py. For this p
ó n B i o m
2 0 1 4 ‐ 2
PHATIC END
fight solid c
amount of
DC, effecto
from tissu
cyte migrat
ave recently
integrin d
S Project), w
cross lymp
purpose, th
é d i c a
0 1 5
DOTHELIAL C
carcinomas
f T lympho
or and mem
e and reac
tion into th
y described
ependent m
we want to
hatic vesse
he candidate
CELLS
s. The
ocytes
mory T
h the
e LVs
d how
mode
study
els in
e will
cont
inflam
tumo
confo
proce
lymp
Biblio
Initia
Lymp
Lymp
inflam
2013
POSS
YES
M á s t e
R e s
ribute to th
mmatory in
or models a
ocal micros
ess, the sub
phatic vesse
ography:
al Afferent L
ph Nodes. T
phatic endo
med lymph
3, 133(9):22
SIBILITY OF
e r U n i v e
e a r c h P
he study the
nfiltrate and
as well as in
scopy‐based
bset of mem
els in human
Lymphatic V
Teijeira A, R
othelium for
hatic vessel
276‐88.
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
e associatio
d T cell mig
n clinical sa
d evidences
mory lymph
n and mous
Vessels Con
ouzaut A, M
rms integrin
s. Teijeira
/NO)
o e n I n v e
r o p o s a l
ns between
gration in s
mples. Ex v
s on the in
hocytes inv
se tumors.
ntrolling Ou
Melero I. Fro
n‐engaging
A, Garasa
e s t i g a c i
E d i t i o n
n lymphatic
spontaneou
vivo and in v
ntervention
olved and t
utbound Leu
ont Immuno
3D structu
S, Peláez R
ó n B i o m
2 0 1 4 ‐ 2
vessel adh
us and tran
vitro experi
of integrin
the peculiar
ukocyte Tra
ol. 2013 De
res during D
R, et al. J I
é d i c a
0 1 5
esive struct
nsplanted m
iments will
n ligands in
rities of aff
affic from Sk
c 9;4: 433.
DC transit a
nvest Derm
tures,
mouse
offer
n this
ferent
kin to
across
matol.
PROJ
Deve
nano
DEPA
Radio
DIRE
Iván
CONT
ipenu
+34 9
SUM
Polym
(SNE
drug
biodi
Radio
radio
biodi
avail
Diffe
direc
M á s t e
R e s
JECT 3
elopment a
oparticles an
ARTAMENT/
opharmacy
CTOR
Peñuelas
TACT
uelas@unav
948 255 400
MMARY
meric nan
DDS) are b
s. Howeve
istribution a
olabelling
onuclides
istribution
ability and
erent appro
ct labeling w
e r U n i v e
e a r c h P
and implem
nd SNEDDS
/LABORATO
Unit. Nucle
v.es
0 ext. 4943
oparticles
eing develo
r, in many
and kinetics
of NPs a
can perm
and help u
the develop
oaches for
with reduce
e r s i t a r i o
r o j e c t P
mentation
for in vivo
ORY
ear Medicin
(CUN)
(NPs) and
oped as ora
cases the
s after their
nd SNEDD
it in vivo
understand
pment of be
radiolabelli
d 99m‐tech
o e n I n v e
r o p o s a l
of radiola
biodistribut
ne Departm
d self‐nano
al nano‐carr
re is very
r administra
DS with e
o non‐inva
the under
etter nano‐
ing nano‐c
hnetium of a
e s t i g a c i
E d i t i o n
belling me
tion studies
ent. CUN.
oemulsifyin
riers that p
few inform
ation.
ither gamm
asive mol
rlying mech
carrier form
arrierrs wil
already form
ó n B i o m
2 0 1 4 ‐ 2
ethodologie
s
g drug de
ermit impr
mation abo
ma or po
ecular ima
hanisms for
mulations.
l be consid
med NPs an
é d i c a
0 1 5
es of polym
elivery sys
roved delive
out their in
ositron em
aging of
r improved
dered, incl
nd SNEDDS
meric
stems
ery of
n vivo
mitting
their
drug
uding
prep
with
The
spec
testin
auto
proce
radio
if co
carri
POSS
M á s t e
R e s
arations, en
fluorine‐18
project wil
ific type of
ng and opt
mation in
edure. Af
olabelled pr
nsidered ap
ed out in la
SIBILITY OF
e r U n i v e
e a r c h P
ncapsulatin
8 complexes
l include th
f nanocarri
timization o
modular c
fter the op
roducts will
ppropriate,
boratory an
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
g of adequ
s or gallium
he theoretic
er, the lab
of the radio
omputer‐co
ptimization
be carried
in vivo stu
nimals.
/NO)Yes
o e n I n v e
r o p o s a l
ate lipophil
m‐68 derived
cal studies
boratory se
olabelling a
ontrolled r
of the ra
out in simu
udies by SP
e s t i g a c i
E d i t i o n
lic radioacti
d synthons a
of the diff
t‐up and e
and quality
adiosynthes
diosynthesi
ulated gastr
ECT‐CT or M
ó n B i o m
2 0 1 4 ‐ 2
ive precurso
and chelato
ferent appr
experimenta
control pro
sis systems
is, stability
ric and inte
MicroPET im
é d i c a
0 1 5
ors and lab
ors.
roaches for
al developm
ocesses an
s of the o
y studies o
stinal fluids
maging cou
elling
each
ment,
d the
verall
f the
s, and
uld be
PROJ
Apta
DEPA
CIMA
DIRE
Fern
CONT
fpasr
SUM
The c
This
The c
stimu
tumo
An a
in th
expre
imm
betw
oper
effec
M á s t e
R e s
JECT 4
mers as a n
ARTAMENT/
A, departme
CTOR
ando Pasto
TACT
rodri@unav
MMARY
challenge in
is especial
current foc
ulate an im
or.
lternative t
he patient’s
essing new
une respon
ween the ef
rating at th
ctive immun
e r U n i v e
e a r c h P
new platform
/LABORATO
ent of onco
r
v.es 948194
n oncology
ly relevant
us in develo
mune respo
to vaccinati
s dissemina
antigens h
nse, wheth
ffector arms
he tumor s
ne response
e r s i t a r i o
r o j e c t P
m in cancer
ORY
logy, Aptam
4700 ext 201
is to treat
in dissemi
oping immu
onse agains
on is to exp
ated tumor
has been am
her vaccine
s of the ant
ite which p
e. Tumors h
o e n I n v e
r o p o s a l
r immunoth
mer Unit
11
tumor lesio
nated tumo
une‐based
st existing,
press new a
r lesions. E
mply docum
e‐induced o
titumor imm
prevent th
have elabora
e s t i g a c i
E d i t i o n
herapy
ons that ar
ors such as
modalities –
albeit weak
antigens in
Enhanced a
mented. The
or naturall
mune respo
e establish
ated immun
ó n B i o m
2 0 1 4 ‐ 2
e hard to d
s hematolog
– cancer va
k, antigens e
tumor cells
antigenicity
e outcome
y occurring
onse and co
ment and/
ne suppress
é d i c a
0 1 5
detect or ac
gical neopl
accination –
expressed i
s in situ, na
y of tumor
of an antit
g, is a ba
ounter mea
/or action o
sive mechan
ccess.
asias.
– is to
in the
amely
cells
umor
lance
sures
of an
nisms
throu
(Treg
of th
enha
supp
using
POSS
Yes
M á s t e
R e s
ugh the rec
g), M2‐type
his project
ance the a
pressive me
g aptamer‐b
SIBILITY OF
e r U n i v e
e a r c h P
cruitment of
e macropha
is to deve
antigenicity
echanisms t
based techn
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
f suppressiv
ages or mye
elop a clini
of the tu
to favor a
nology.
/NO)
o e n I n v e
r o p o s a l
ve lymphoc
eloid‐derive
ically usefu
umor and
potent nat
e s t i g a c i
E d i t i o n
cytes, such
ed suppress
ul and broa
to diminis
ural anti‐tu
ó n B i o m
2 0 1 4 ‐ 2
as foxp3+ r
sor cells (M
adly applica
h the imp
umor immu
é d i c a
0 1 5
regulatory T
MDSC). The
able metho
pact of imm
une respon
T cells
focus
od to
mune
se by
PROJ
Mole
new
DEPA
Mole
Univ
DIRE
Isabe
CONT
otan
SUM
Neur
sugg
Hunt
onse
One
mech
to de
what
M á s t e
R e s
JECT 5
ecular basis
gene thera
ARTAMENT/
ecular and C
ersity of Na
CTOR
el Pérez‐Ota
TACT
MMARY
ral circuits
est that n
tington’s (H
et and long
primary c
hanisms tha
evelopment
t has preven
e r U n i v e
e a r c h P
s of Hunting
py approac
/LABORATO
Cellular Neu
avarra Medi
año and Son
s, +34 948 1
are made
neurodegen
HD) start w
before neu
ause seem
at trigger sy
tal stages.
nted the de
e r s i t a r i o
r o j e c t P
gton´s disea
ch
ORY
urobiology L
ical School
nia Marco
94700 x200
up of neur
nerative di
ith synapse
uronal deat
ms to be a
ynapse loss
However,
evelopment
o e n I n v e
r o p o s a l
ase: Identify
Laboratory,
09
rons conne
iseases suc
e dysfunctio
th; they are
pathologic
(or “prunin
the molecu
t of rational
e s t i g a c i
E d i t i o n
ying disrup
, Neuroscie
ected by sy
ch as Alzh
on and loss
e collective
cal reactiva
ng”) and sh
ular basis is
e‐based the
ó n B i o m
2 0 1 4 ‐ 2
ted signalli
nce Depart
napses. R
heimer’s, P
s decades b
ely called “s
ation in ad
ould norma
s unknown
erapies.
é d i c a
0 1 5
ng and test
tment, CIMA
Recent evid
Parkinson´s
before sym
synaptopath
dult neuro
ally be restr
in most ca
ting a
A and
dence
and
ptom
hies”.
ns of
ricted
ases ,
A ke
gluta
expre
deve
expe
matu
react
comp
HD o
The g
syna
mole
thera
We a
basic
such
POSS
M á s t e
R e s
ey pruning
amate rece
essed durin
elopment b
erience from
uration (Rob
tivation o
promising c
or cocaine a
goal of this
ptic connec
ecular biolo
apy approac
anticipate t
c principles
as AD.
SIBILITY OF
e r U n i v e
e a r c h P
factor disc
ptors (NMD
ng early po
by maintain
m the ext
berts et al,
f GluN3A
cognitive ab
buse (Marc
project wil
ctivity and
ogy techniq
ch based up
that the info
underlying
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
covered by
DARs) that
ostnatal and
ning synaps
ernal worl
2009, Fiuza
expressio
bilities, and
co et al, Yua
l be: 1) to d
cognition
ques in gen
pon silencin
ormation g
g neurodeg
/NO) YES
o e n I n v e
r o p o s a l
y our group
contain th
d juvenile
ses in an
d, which
a et al., 201
on trigger
has been a
an et al).
define signa
in HD usin
netically mo
ng of GluN3
enerated m
generation
e s t i g a c i
E d i t i o n
p is a nov
e GluN3A s
stages. It
immature
is the mai
13). But re
s synapse
associated
aling pathw
ng a combi
odified mic
3A expressio
may be valu
not only in
ó n B i o m
2 0 1 4 ‐ 2
el subclass
subunit. G
works as a
state unti
in driving
ecent work
e dysfunct
to CNS path
ays by whic
nation of b
ce; 2) to te
on in a mou
able for un
n HD but in
é d i c a
0 1 5
s of NMDA
GluN3A is m
a gate for
l the arriv
force for
shows the
tion and
hologies su
ch GluN3A a
biochemica
est a new
use model o
nderstandin
n other dis
A‐type
mainly
brain
val of
brain
adult
loss,
uch as
alters
l and
gene
of HD.
ng the
eases
PROJ
CHAR
FUNC
DEPA
Lab 3
DIRE
Rafae
CONT
ralda
SUM
Most
mod
catal
enzy
nece
obse
mice
and t
can i
with
comp
M á s t e
R e s
JECT 6
RACTERIZAT
CTIONS.
ARTAMENT/
3.03, Dept H
CTOR
el Aldabe
TACT
MMARY
t eukaryotic
ification ha
lyze this re
me acetyla
essary for
erved also t
e and huma
tumor grow
inhibit spec
cellular mo
pounds as i
e r U n i v e
e a r c h P
TION OF N
/LABORATO
Hepatology
es, 9481947
c proteins a
as not been
eaction is N
ates, amon
a proper
hat this enz
ans. Similarl
wth in mice.
cifically this
otility and
n vitro NatB
e r s i t a r i o
r o j e c t P
AA25 KNOC
ORY
and Gene T
700 Ext 300
are aminote
n clearly el
NatB, integ
g others, a
actin cytos
zyme is upr
y, the inhib
. Based on t
enzymatic
cell cycle d
B inhibitors
o e n I n v e
r o p o s a l
CK‐OUT MI
Therapy, CI
04
erminally ac
ucidated. O
rated by tw
actin and t
skeleton fu
regulated w
bition of th
these data w
activity, in
developmen
that disorg
e s t i g a c i
E d i t i o n
ICE: EFFECT
MA
cetylated al
One of the
wo subunit
tropomyosi
unction an
when hepato
is enzyme
we have se
vitro and i
nt. We have
ganize actin
ó n B i o m
2 0 1 4 ‐ 2
TS ON MUS
though the
enzymatic
ts, Naa20 a
n, being th
d organiza
ocarcinoma
blocks cellu
arched for
n cultured
e already id
cytoskeleto
é d i c a
0 1 5
SCLE AND
e function o
complexes
and Naa25.
his modific
ation. We
a is develop
ular prolifer
compounds
cells, interf
dentified se
on and bloc
LIVER
of this
s that
. This
cation
have
ped in
ration
s that
fering
everal
ck
tumo
NatB
We h
regu
inhib
there
or th
indic
mult
In th
Naa2
purp
after
of N
histo
expe
Grou
1. Im
carci
2008
M á s t e
R e s
or growth
B as a new t
have genera
lated by N
bition of thi
efore we ha
hat in all
cate that Na
inucleation
e present p
25 gene, pa
pose we wil
r several tre
aa25 inacti
ological ana
eriments wit
up publicatio
mplication
nogenesis.
8, 58:7296‐3
e r U n i v e
e a r c h P
in xenograf
herapeutica
ated Naa25
NatB enzym
s enzyme c
ave generat
the tissues
aa25 ablatio
and genera
project we p
aying specia
l analyze he
eatments to
vation. We
alysis. Addit
th cultured
ons related
of human
Ametzazur
306.
e r s i t a r i o
r o j e c t P
ft animal m
al candidate
5 KO anima
me and to
could have.
ted conditio
s after tam
on reduces
ates heart h
propose to a
al attention
eart, muscl
o determine
e will obtain
tionally we
hepatocyte
to the proj
N‐alpha‐ac
rra A, Larre
o e n I n v e
r o p o s a l
models. The
e.
ls in order
predict th
This mutat
onal KO mic
moxifen ad
hepatocyte
hypertrophy
analyze in d
to liver an
e and hear
e if their fun
n tissue sam
e will isolat
es and chara
ject:
cetyltransfe
ea E, Civeir
e s t i g a c i
E d i t i o n
erefore we
to identify
e potentia
tion is emb
ce with Naa
ministration
es proliferat
y and fibros
detail the co
d muscle re
rt functiona
nction is com
mples for m
e mouse h
acterize the
erase 5 in
ra MP, Prie
ó n B i o m
2 0 1 4 ‐ 2
are intere
the molecu
l adverse e
ryonic letha
a25 deleted
n. Our pre
tion, promo
sis.
onsequence
elated phen
lity in basa
mpromised
molecular, b
hepatocytes
em.
cellular p
eto J, Aldab
é d i c a
0 1 5
ested in va
ular mechan
effects tha
al, before 7
d just in the
eliminary re
otes hepato
es of inactiv
notypes. Fo
al condition
as consequ
biochemica
s for perfor
roliferation
be R. Onco
lidate
nisms
t the
7 dpc,
e liver
esults
ocytes
vating
or this
s and
uence
al and
rming
n and
gene.
2. C
comp
2009
3. Th
Lasa
Dem
Alda
POSS
YES
M á s t e
R e s
haracteriza
plex. Ametz
9 Aug 4;3 Su
he NatB N‐t
M, Polevo
eyer K, Hol
be R. Proc N
SIBILITY OF
e r U n i v e
e a r c h P
tion of th
zazurra A, G
uppl 6:S4.
terminal ac
oda B, Gaz
e K, Larrea
Natl Acad Sc
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
e human
Gázquez C,
etylome: su
zquez C, El
E, Timmerm
ci U S A. 201
/NO)
o e n I n v e
r o p o s a l
Nalpha‐ter
Lasa M, La
ubstrates a
losegui‐Arto
man E, Prie
12. Jul 31;1
e s t i g a c i
E d i t i o n
minal acet
arrea E, Prie
nd function
ola A, Soo
to J, Arnese
09(31):1244
ó n B i o m
2 0 1 4 ‐ 2
yltransferas
eto J, Aldab
nal insigths.
Kim D, de
en T, Sherm
49‐54.
é d i c a
0 1 5
se B enzy
be R. BMC
. Van Damm
e Juan‐Pard
man F, Geva
matic
Proc.
me P,
do E,
ert K,
PROJ
Inhib
clinic
DEPA
Depa
Area
DIRE
Javie
CONT
jscas
SUM
Intro
child
prog
histo
the p
recen
have
will
supp
M á s t e
R e s
JECT 7
bition of the
cal prognos
ARTMENT/L
artment of B
: cancer res
CTOR
er Sáez Cast
TACT
stresana@u
MMARY
oduction: M
hood tumo
nosis), whi
ological type
prognosis o
nt years, m
e been sugg
assess whe
posedly tum
e r U n i v e
e a r c h P
e sonic hed
is in brain t
LABORATOR
Biochemistr
search (Tum
resana
nav.es
Medulloblast
or. Some M
ile others a
e (intermed
of MB only
many MB ha
gested: the
ether the p
mor cells hav
e r s i t a r i o
r o j e c t P
gehog path
umors.
RY
ry and Gene
mor Biology
toma (MB)
B have a m
are anaplas
diate progn
counting w
ave been st
so‐called W
primary cili
ve, may help
o e n I n v e
r o p o s a l
hway and ro
etics, Schoo
Laboratory
is the mos
morphologic
stic (poor
nosis) . But
with the hist
tudied at t
Wnt, Shh, gr
ium, a kind
p in assessi
e s t i g a c i
E d i t i o n
ole of the p
ol of Science
y)
st common
cal pattern o
prognosis),
one canno
topathologi
he genetic
roup 3 and
d of flagell
ng the prog
ó n B i o m
2 0 1 4 ‐ 2
primary ciliu
es
and malign
of desmopl
and other
t always ac
ical variable
level, and
group 4. In
um that n
gnosis of MB
é d i c a
0 1 5
um as a fact
nant intrac
lastic type (
rs are of c
ccurately pr
es. Therefo
four sets o
n this proje
normal cells
B.
tor of
ranial
(good
classic
redict
re, in
of MB
ct we
s and
Hypo
aggre
Ther
grou
Obje
1. To
2. To
3. C
histo
recur
4. In
(cycl
POSS
Yes, t
BIBLI
‐ Roh
2
‐ Lan
p
‐ Ellis
n
M á s t e
R e s
othesis: We
essive (des
efore we t
ps 3 and 4 w
ectives:
o determine
o determine
Correlation
ological and
rrence, met
n vitro and
opamine) a
SIBILITY OF
this project
IOGRAPHY
hatgi R, et a
2007;317:37
ncaster MA,
primary ciliu
son DW, et
non‐SHH/W
e r U n i v e
e a r c h P
e think the
smoplastic)
think the m
would not e
e the inciden
e the expres
of the pr
d molecula
tastasis, res
d in vivo t
and Gli (siRN
PhD (YES/N
t can be con
al. Patched1
72–6.
, et al. Subc
um. Nat Cel
t al. Medull
NT molecul
e r s i t a r i o
r o j e c t P
primary c
to more
majority of
express it, o
nce, morph
ssion of mo
resence of
ar groups
sponse to tr
treatment a
NA)
NO)
ntinued with
1 regulates
cellular spa
l Biol 2011;
oblastoma:
lar subgrou
o e n I n v e
r o p o s a l
cilium disap
aggressive
Shh‐MBs e
or would ex
hology and l
lecules of th
primary c
of MB an
reatment.
assays aga
h a PhD (do
hedgehog s
atial regulat
13:700–7.
: clinicopath
ps. Acta Ne
e s t i g a c i
E d i t i o n
ppears whe
types (cla
express the
press it in a
ength of pr
he Shh path
cilium and
nd with m
inst Shh in
octoral thes
signaling at
tion of cano
hological co
europathol 2
ó n B i o m
2 0 1 4 ‐ 2
en MBs pro
assic and
primary c
n aberrant
imary cilium
hway in MB
Shh activ
markers of
n MB at t
is).
the primary
onical Wnt
orrelates of
2011;121:38
é d i c a
0 1 5
ogress from
anaplastic
ilium, while
form.
m in MB.
B.
vation with
clinical co
two levels:
ry cilium. Sc
signalling a
f SHH, WNT
81–96.
m less
MB).
e MB
h the
ourse:
Smo
cience
at the
T, and
PROJ
Fabr
DEPA
Canc
DIRE
Carlo
Ana
CONT
Emai
Phon
SUM
Ther
bioch
phys
deve
resem
canc
matr
is to
clinic
M á s t e
R e s
JECT 8
ication and
ARTAMENT/
cer Imaging
CTOR
os Ortiz de S
Rouzaut Su
TACT
il: codesolo
ne: CIMA x5
MMARY
e is an in
hemical pr
iological c
elopment o
mbling thos
er metasta
rices in canc
provide in
cal contexts
e r U n i v e
e a r c h P
characteriz
/LABORATO
Laboratory
Solórzano (d
birá (co‐dir
rzano@una
5019
ncreasing n
roperties o
ontext. Ac
of biomime
se of brain,
asis are fre
cer cell mig
ndustry wit
s.
e r s i t a r i o
r o j e c t P
zation of bio
ORY
y, Oncology
director)
ector).
av.es
need of m
of tumours
ccordingly,
etic hydrog
liver and lu
equently e
ration expe
th micro‐de
o e n I n v e
r o p o s a l
omimetic ge
Departmen
models in w
s in enviro
the overa
gels with m
ung. This hy
established.
eriments wit
evices to te
e s t i g a c i
E d i t i o n
els for cell m
nt, CIMA.
which to s
onments th
arching goa
mechanical
ydrogels sim
Therefore
thin microf
est new an
ó n B i o m
2 0 1 4 ‐ 2
migration st
study the
hat closely
al of this
and chem
mulate the c
e we will
luidic devic
ti‐metastat
é d i c a
0 1 5
tudies
biophysical
y resemble
project is
mical prope
context in w
use these
ces. Our fina
tic drugs in
l and
e the
s the
erties
which
new
al aim
n pre‐
The s
‐ Per
of th
‐ Fab
‐ Glo
‐ Loc
Scan
‐ Per
fabri
This
Com
with
micro
BioM
mech
POSS
Yes,
stipe
M á s t e
R e s
steps the ca
rform a bibl
e organs of
bricate gels
obally chara
cally chara
ning Confoc
rform funct
cated ad‐ho
work is pa
petitivenes
personnel
oenvironme
Mems and
hanical char
SIBILITY OF
but it is d
end.
e r U n i v e
e a r c h P
andidate sh
iography‐ba
f interest.
with the re
cterize the
acterize the
cal Microsc
tional analy
oc, their me
art of an e
s (DPI2012‐
of CIMA’s C
ent group.
Mechanica
racterizatio
Ph.D. (YES/
dependent
e r s i t a r i o
r o j e c t P
ould follow
ased descri
quired prop
gels using r
e gels usin
opy (LSCM)
yses of canc
etastatic po
existing pro
‐38090‐C03
Cancer Imag
In addition,
al Enginee
n of gels us
/NO)
on obtaini
o e n I n v e
r o p o s a l
w to achieve
ption of the
perties and
rheology an
ng Atomic
)
cer cell mig
otential and
oject funde
3‐02) and w
ging Labora
, the candid
ring group
sing Rheolog
ng externa
e s t i g a c i
E d i t i o n
e this are:
e compositi
introduce t
d Scanning
Force Mic
gration insid
the action
ed by the
ill be carrie
atory, Imagi
date will ha
ps at CEIT
gy, SEM and
l funding t
ó n B i o m
2 0 1 4 ‐ 2
ion of the m
them into m
Electron M
croscopy (A
de the mic
of anti‐inte
Ministry o
d out in clo
ng Core Fac
ave active s
(San Seb
d TFM.
to pay for
é d i c a
0 1 5
mimetic ma
micro‐device
Microscopy (
AFM) and
rofluidic de
egrin drugs.
of Economy
ose collabor
cility, and t
upport from
bastián) for
the tuition
trices
es.
(SEM)
Laser
evices
y and
ration
umor
m the
r the
n and
PROJ
Study
thera
DEPA
Labo
DIRE
Rube
Dani
CONT
Emai
Tel. 9
SUM
Lung
unde
respo
ident
of th
host
is ac
recen
have
M á s t e
R e s
JECT 9 (ASIG
y of comp
apeutic targ
ARTAMENT/
oratory of Bi
CTOR
en Pio Oses
el Ajona Ma
TACT
il: dajonama
948194700
MMARY
g cancer is
erstanding
onse will le
tification of
he innate im
elements. T
companied
nt years ha
e proposed t
e r U n i v e
e a r c h P
GNADO)
lement act
gets and dia
/LABORATO
iomarkers.
artinez‐Polo
ext. 1018
s the lead
of the mo
ead to the
f new diagn
mmune resp
There is suf
by an incr
as identified
that lung ca
e r s i t a r i o
r o j e c t P
tivation in
agnostic ma
ORY
Oncology D
o
ing cause
olecular in
developm
nostic mark
ponse that
fficient bas
reased capa
d new and
ancer cells g
o e n I n v e
r o p o s a l
lung cance
arkers.
Division. CIM
of cancer‐
nteractions
ment of bet
kers. The co
has evolve
is to propo
acity to acti
surprising
generate co
e s t i g a c i
E d i t i o n
er cells for
MA
‐related de
between
tter antican
omplement
d as a first
se that lung
ivate comp
roles for c
omplement
ó n B i o m
2 0 1 4 ‐ 2
the identi
eath world
tumors an
ncer therap
system is a
defence ag
g neoplastic
lement. Sig
complemen
C5a, a pow
é d i c a
0 1 5
ification of
dwide. A b
nd the imm
pies, and to
an essentia
gainst unwa
c transform
gnificant wo
nt in cancer
werful
f new
better
mune
o the
l part
anted
mation
ork in
r. We
proin
chro
the p
we h
be o
resul
the
incre
comp
clinic
a stra
utilit
treat
POSS
Yes (
M á s t e
R e s
nflammator
nic inflamm
pathway by
have found
of value for
lts, the idea
evaluation
easing inter
plement ac
cal utility of
ategy for lu
y of compl
tment of lun
SIBILITY OF
conditional
e r U n i v e
e a r c h P
ry molecule
mation, ang
y which com
that lung t
r the diagn
a of blockin
of comple
rest. In this
ctivation in
f markers o
ung cancer t
ement rela
ng cancer.
Ph.D. (YES/
l on financia
e r s i t a r i o
r o j e c t P
e, which co
iogenesis, a
mplement is
tumors gen
nosis and p
ng complem
ement pro
project we
lung canc
f compleme
treatment. T
ted protein
/NO)
al support)
o e n I n v e
r o p o s a l
ontributes
and immun
s activated i
erate C4d,
prognosis o
ment for the
oducts as l
e will chara
er (both in
ent, and th
This study w
ns and to id
e s t i g a c i
E d i t i o n
to tumor
osuppressio
in lung canc
a complem
f lung canc
e treatmen
lung cance
acterize the
n cell lines
e efficacy o
will allow u
dentify new
ó n B i o m
2 0 1 4 ‐ 2
progression
on. We also
cer cells. M
ment split‐p
cer. On the
t of lung ca
r biomarke
e molecular
and prima
of complem
s to evaluat
w molecular
é d i c a
0 1 5
n by prom
o have iden
ore import
roduct that
e basis of
ancer, as w
ers, has g
r mechanism
ary tumors)
ment inhibiti
te the diagn
r targets fo
moting
ntified
antly,
t may
these
well as
ained
ms of
), the
on as
nostic
or the
PROJ
Role
DEPA
Liver
Healt
DIRE
Dr. Je
CONT
Emai
Tel: +
SUM
Polyc
dilata
requ
hepa
pain,
Euro
polyc
PCLD
M á s t e
R e s
JECT 10 (AS
of Endopla
ARTAMENT/
r Diseases G
th Research
CTOR
esús M. Bañ
TACT
il: jesus.ban
+34 943006
MMARY
cystic liver
ation and/o
iring liver t
atic cysts ca
, gastro‐eso
pean Unio
cystic kidne
Ds is the res
e r U n i v e
e a r c h P
IGNADO)
smic Reticu
/LABORATO
Group, Dep
h Institute (
ñales (Co‐di
nales@biod
6067 (Office
diseases (
or cyst dev
transplanta
auses sympt
ophageal ref
on are affe
ey disease. W
ult of hyper
e r s i t a r i o
r o j e c t P
ulum Stress
ORY
artment of
Donostia U
irector: Dra
onostia.org
e)/ +34 9430
(PCLDs) are
velopment,
ation as the
toms such a
flux, and dy
ected by P
We have re
rproliferatio
o e n I n v e
r o p o s a l
in the Path
f Liver and G
niversity Ho
. María J. P
g/jmbanales
006125 (Lab
e genetic
which bec
e only ther
as abdomin
yspnea. It is
PCLDs, and
ecently dem
on, hyperse
e s t i g a c i
E d i t i o n
hogenesis of
Gastrointes
ospital), San
erugorria).
b)
disorders c
come prog
rapeutic op
nal distensio
s estimated
often, the
monstrated t
ecretion, ma
ó n B i o m
2 0 1 4 ‐ 2
f Polycystic
stinal Disea
n Sebastián
characterize
ressively m
ption. The l
on, local pre
that 1 milli
ese patient
that hepatic
atrix‐metall
é d i c a
0 1 5
Liver Disea
ses. Biodon
(Gipuzkoa)
ed by bile
more severe
large volum
essure with
on people i
ts also de
c cystogene
oprotease
ses
nostia
).
duct
e and
me of
back
in the
velop
esis in
hype
chola
Some
retic
that
cellu
mark
ASNS
well
chara
polyc
abilit
mark
POSS
This
M á s t e
R e s
eractivity an
angiocytes)
e of the ge
ulum (ER).
occurs whe
lar alterati
kers involve
S, CHOP, et
as in norm
acteristic o
cystic chola
ty of ursode
kers will be
SIBILITY OF
project will
e r U n i v e
e a r c h P
nd alteratio
.
nes mutate
We hypoth
en unfolded
ions. Thus,
ed in the un
c will be
mal and poly
of ER stress
angiocytes
eoxycholic
studied in p
Ph.D. (YES/
be continu
e r s i t a r i o
r o j e c t P
on in the p
ed in PCLDs
esize that P
d and misfo
the expre
nfolded pro
analyzed in
ycystic rat c
s, such as
by transm
acid (UDCA
polycystic ra
/NO)
ued with a P
o e n I n v e
r o p o s a l
pattern of
s encode fo
PCLDs may
olded prote
ession leve
otein respo
n normal an
cholangiocy
ER dilatati
mission elec
A) to modu
at (PCK rat)
Ph.D. (docto
e s t i g a c i
E d i t i o n
microRNAs
or proteins
be associat
ins accumu
els (mRNA
nse (UPR)
nd polycysti
ytes in cultu
on, will be
ctron micro
late the ex
livers.
oral thesis).
ó n B i o m
2 0 1 4 ‐ 2
in the bile
located in t
ted with ER
ulate in the
and prote
IRE1α, PE
c human ch
ure. Morpho
e evaluated
oscopy (TE
pression lev
é d i c a
0 1 5
e duct cells
the endopla
stress, an e
ER and res
ein) of diff
ERK, ATF6, X
holangiocyt
ological cha
d in norma
M). Finally
vels of ER s
s (i.e.
asmic
event
sult in
ferent
XBP1,
es, as
anges
l and
y, the
stress
PROJ
Gene
DEPA
Labo
Prog
DIRE
Glori
CONT
ggase
SUM
With
for in
cure
disea
gene
objec
highe
vecto
that
anim
M á s t e
R e s
JECT 11
e therapy of
ARTAMENT/
oratory of g
ram. CIMA.
CTOR
ia Gonzalez
TACT
egui@unav
MMARY
h of the obj
nherited liv
except fo
ases: Acute
e therapy v
ctive of thi
er efficiency
ors will be
showed a b
mal model
e r U n i v e
e a r c h P
f inherited
/LABORATO
gene thera
.
Aseguinola
v.es
ective of ou
ver metabo
r liver tran
e intermitte
vector we a
s project w
y of liver tr
tested in c
better capa
e r s i t a r i o
r o j e c t P
liver metab
ORY
py of liver
aza
ur laborato
lic disorder
nsplantation
ent porphyr
are using is
will be the
ansduction
cell culture
city to tran
o e n I n v e
r o p o s a l
bolic disorde
r diseases.
ry is the de
rs. Most of
n. We are
ria (AIP), W
s based on
developme
based on i
and anima
nsduce the l
e s t i g a c i
E d i t i o n
ers
Gene Ther
evelopment
them are r
currently w
Wilson disea
the adeno
ent of new
ntroducing
l models u
liver will be
ó n B i o m
2 0 1 4 ‐ 2
rapy and G
t of gene th
rare disease
working of
ase and Hyp
associated
AAV based
capsid mod
sing report
e tested in a
é d i c a
0 1 5
Gene Regul
herapy strat
es that hav
f three diff
peroxaluria
virus. The
d vectors w
dification. T
ter genes. T
a Wilson di
lation
tegies
e not
ferent
. The
main
with a
Those
Those
sease
POSS
YES i
M á s t e
R e s
SIBILITY OF
f fellowship
e r U n i v e
e a r c h P
Ph.D. (YES/
p
e r s i t a r i o
r o j e c t P
/NO)
o e n I n v e
r o p o s a l
e s t i g a c i
E d i t i o n
ó n B i o m
2 0 1 4 ‐ 2
é d i c a
0 1 5
PROJ
Treat
block
DEPA
Labo
DIRE
Pablo
CONT
psaro
SUM
Altho
carci
mont
respo
assoc
of th
block
(CTLA
mod
proje
whic
M á s t e
R e s
JECT 12
tment of h
kade of imm
ARTAMENT/
oratory of Ex
CTOR
o Sarobe, D
TACT
obe@unav.
MMARY
ough biolog
noma (HCC
ths. Immun
onses to re
ciated to tu
hese pathwa
kade using
A‐4, PD‐1/P
els, but also
ect is to stu
h includes t
e r U n i v e
e a r c h P
hepatocellu
munosuppre
/LABORATO
xperimenta
Diana Llopiz.
.es; diallo@
gical therap
C), their res
notherapy is
eject tumor
umors impa
ays may en
neutralizin
PD‐L1, etc)
o in patient
dy the anti
the biologic
e r s i t a r i o
r o j e c t P
ular carcino
ession
ORY
l Immunolo
.
unav.es 81
pies are cur
ults are stil
s an alterna
r cells. How
air the effica
nhance the
g antibodie
is showing
s with diffe
tumor effic
cal therapy
o e n I n v e
r o p o s a l
oma by co
ogy, CIMA.
3009‐81300
rrently used
l poor, prol
ative strateg
wever, imm
acy of thes
efficacy of
es against s
g promising
rent types o
cacy in a HC
agent Soraf
e s t i g a c i
E d i t i o n
mbination
07.
d for the t
longing pat
gy which se
munosuppre
e protocols
immunothe
several imm
g results no
of cancer. T
CC model of
fenib and an
ó n B i o m
2 0 1 4 ‐ 2
of biologic
reatment o
ient’s surviv
eeks to enh
ssive molec
s, suggestin
erapy. Imm
munosuppre
ot only in p
Thus, the aim
f a therapeu
ntibodies ag
é d i c a
0 1 5
cal therapy
of hepatoce
val only in a
hance anti‐t
cules comm
ng that inhib
mune check‐
essive path
preclinical t
m of the pr
utic combin
gainst
y and
ellular
a few
umor
monly
bition
‐point
hways
umor
esent
nation
imm
comb
analy
imm
unde
Thes
imm
flow
gene
POSS
Depe
M á s t e
R e s
unosuppres
binations a
yzed in trea
unological
erstand the
e will inclu
une cell po
cytometry,
e expression
SIBILITY OF
ending on th
e r U n i v e
e a r c h P
ssive molec
nd in vivo
ated mice.
pathways,
e immunolo
ude ex vivo
opulations,
, analysis of
n by RT‐PCR
Ph.D. (YES/
he ability of
e r s i t a r i o
r o j e c t P
cules. Mice
anti‐tumor
Moreover,
in vivo an
ogical mec
o experime
using techn
f cell functio
R, and adopt
/NO)
f the studen
o e n I n v e
r o p o s a l
bearing H
r effect (tu
since block
nd in vitro
chanisms re
nts as wel
niques such
ons by ELISA
tive transfe
nt to obtain
e s t i g a c i
E d i t i o n
CC tumors
umor growt
king antibo
experimen
esponsible
l as experi
h as cell cu
A, ELISPOT,
er of lympho
n funds to su
ó n B i o m
2 0 1 4 ‐ 2
will be tre
th, animal
dies may m
nts will be
for the ob
ments afte
ltures, cell
flow cytom
ocytes.
upport the
é d i c a
0 1 5
eated with
survival) w
modulate se
e carried o
bserved re
er stimulatio
phenotypin
metry, analy
PhD studies
these
will be
everal
ut to
esults.
on of
ng by
ysis of
s.
PROJ
Role
DEPA
Labo
CUN,
CIMA
DIRE
Mait
CONT
mait
SUM
Mam
to pr
long
chara
expre
patte
like t
regu
that
epige
M á s t e
R e s
JECT 13
of lncRNAs
ARTAMENT/
oratory whe
, CIMA etc.
A, Oncology
CTOR
te Huarte M
TACT.
ehuarte@u
MMARY
mmalian cel
rotein codin
noncoding
acterized. T
ession, oft
erns sugges
the p53 pa
lated by p5
these p53
enetic lands
e r U n i v e
e a r c h P
s in cancer e
/LABORATO
ere the proj
y Departme
Martínez
unav.es
ls encode t
ng genes, h
g RNAs (ln
The few tha
ten throug
st that some
thway. Our
53 and stron
3‐regulated
scape of cel
e r s i t a r i o
r o j e c t P
epigenetics
ORY
ect will be
nt
thousands o
however lac
ncRNAs) ex
at have sho
h epigenet
e lncRNAs a
r laboratory
ngly enriche
lncRNAs p
lls. In this p
o e n I n v e
r o p o s a l
carried out
of mysterio
ck coding c
ist, only fe
w powerfu
tic mechan
are involved
y has ident
ed in the n
play a crit
roject the s
e s t i g a c i
E d i t i o n
t indicating
ous RNA mo
capacity. Alt
ew of them
l biological
nisms. Sign
d in cellular
ified severa
ucleus of tu
ical role in
student will
ó n B i o m
2 0 1 4 ‐ 2
Departmen
olecules str
though tho
m have be
roles as reg
nificantly, t
pathways c
al lncRNAs
umor cells.
n cancer b
investigate
é d i c a
0 1 5
nt, Area, Fa
ructurally si
ousands of
een functio
gulators of
their expre
critical in ca
transcriptio
We hypoth
by affecting
e the
culty,
imilar
these
onally
gene
ession
ancer,
onally
hesize
g the
mech
that,
techn
DNA
geno
regu
POSS
Indic
Yes
M á s t e
R e s
hanisms of
he/she w
niques to d
deep sequ
omic loci rec
lation and r
SIBILITY OF
cate if the p
e r U n i v e
e a r c h P
epigenetic
will apply te
detect RNA
uencing. Th
cognized by
role in canc
Ph.D. (YES/
roject could
e r s i t a r i o
r o j e c t P
regulation
echniques f
association
rough these
y the RNA a
er.
/NO)
d be continu
o e n I n v e
r o p o s a l
by p53‐reg
for RNA im
n with chro
e experime
and will gain
ued with a
e s t i g a c i
E d i t i o n
gulated lncR
maging (RN
matin (ChIR
ents we wil
n insight int
Ph. D. (doct
ó n B i o m
2 0 1 4 ‐ 2
RNAs in can
A‐FISH) tog
RP and ChA
l be able to
to their mec
toral thesis)
é d i c a
0 1 5
ncer cells. T
gether with
ART) followe
o determin
chanism of
)
To do
h the
ed by
e the
gene
PROJ
Func
DEPA
Adhe
Med
DIRE
Dr. S
CONT
silvev
SUM
KRAS
tumo
and
rema
onco
thera
to de
The
gene
spec
trans
M á s t e
R e s
JECT 14 (AS
ctional chara
ARTAMENT/
esion and M
ical Researc
CTOR
ilvestre Vic
TACT
vicent@una
MMARY
S represent
ors. Mutatio
pancreatic
ained refrac
ogenes such
apies have
evelop strat
current pro
es. In this st
ifically reg
scriptomic s
e r U n i v e
e a r c h P
IGNADO)
acterization
/LABORATO
Metastasis L
ch (CIMA)
ent Cambra
av.es; 948 1
s the domin
ons in KRAS
adenocarc
ctory to the
h as EGFR o
been develo
tegies desig
oposal stem
udy an inte
gulated by
signature of
e r s i t a r i o
r o j e c t P
n of oncoge
ORY
Laboratory
a
194700 (ext
nant oncog
S are found
cinomas. G
erapeutic in
or fusion on
oped. Thus,
gned to reac
ms from a p
grative cros
mutant
f overexpre
o e n I n v e
r o p o s a l
ne‐regulate
(Lab 102),
t. 1003).
gene driving
d in epitheli
Given the u
nhibition. T
ncoproteins
, a paradigm
ch this unm
preliminary
ss‐species g
KRAS was
essed genes
e s t i g a c i
E d i t i o n
ed mechani
Oncology D
g human tum
ial cancer ty
uniqueness
his is in sha
such as BC
m switch of
et clinical n
study aim
gene‐expres
followed.
representa
ó n B i o m
2 0 1 4 ‐ 2
sms in KRAS
Division, Ce
morogenes
ypes includ
of KRAS a
arp contras
CR‐ABL or E
this trend
need.
ed to ident
ssion analys
This stra
ative of mou
é d i c a
0 1 5
S‐driven ca
enter for Ap
is in 30% o
ding lung, co
as a target
st to other
EML‐ALK4 fo
remains im
tify KRAS‐re
sis to identi
ategy iden
use and hum
ncers
pplied
f human
olorectal
t, it has
mutated
or which
perative
egulated
fy genes
tified a
man
canc
some
KRAS
funct
achie
a) Ch
canc
b) Fu
onco
REFE
Malv
mort
RAS
3:459
POSS
We a
the p
M á s t e
R e s
ers harbori
e of these g
S in human
tional relev
eve this goa
haracterizat
er specime
unctional di
ogenesis usi
ERENCES
vezzi, M., B
tality predic
oncogenes
9‐65
SIBILITY OF
anticipate t
project to b
e r U n i v e
e a r c h P
ng KRAS mu
genes will co
KRAS oncog
vance of su
al:
tion of the
ns and thei
ssection in
ng a loss‐of
ertuccio, P.
ctions for th
s: the first
Ph.D. (YES)
that the fin
e continued
e r s i t a r i o
r o j e c t P
utations. Ba
onstitute cr
genesis. Thu
uch KRAS r
e expressio
r clinico‐pat
vitro and in
f‐function a
., Levi, F., L
he year 2013
30 years. M
dings deriv
d with a Ph.
o e n I n v e
r o p o s a l
ased on the
ritical eleme
us, the goa
regulated g
n levels of
thological im
n vivo of th
approach in
La Vecchia,
3. Ann Onco
Malumbres
ved from th
. D. (doctora
e s t i g a c i
E d i t i o n
se findings,
ents of the
l of this pro
genes. A se
f single KRA
mplications
e role of KR
cancer cell
C., and Ne
ol 24:792‐8
s M, Barbac
his project w
al thesis).
ó n B i o m
2 0 1 4 ‐ 2
, the curren
signaling ca
oposal is to t
eries of aim
AS‐regulate
s.
RAS‐regulat
lines.
egri, E. 2013
00.
cid M. 200
will open th
é d i c a
0 1 5
nt hypothes
ascade trigg
test the clin
ms are pla
ed genes in
ted genes in
3. European
03. Nat Rev
he possibilit
is is that
gered by
nical and
nned to
n human
n human
n cancer
v Cancer
ty for
PROJ
Role
DEPA
Labo
Divis
DIRE
Marí
CONT
mum
948 1
SUM
Hear
costs
The s
remo
num
Myo
such
impa
M á s t e
R e s
JECT 15
of oxidative
ARTAMENT/
oratory of M
sion of Card
CTOR
ía de Ujué M
TACT
moreno@un
194700 ext
MMARY
rt failure (H
s, bad progn
structural c
odelling, inc
ber of capil
cardial fibro
as hyperte
act, since it
e r U n i v e
e a r c h P
e stress in t
/LABORATO
Myocardial r
iovascular S
Moreno Zula
nav.es
. 3022
HF) is a very
nosis despit
changes tha
clude the d
laries and t
osis is incre
ension and
results in in
e r s i t a r i o
r o j e c t P
the regulatio
ORY
emodelling
Sciences, CI
ategui
y important
te state‐of‐t
at take place
death and
the excessiv
eased in pat
diabetes. T
ncreased sti
o e n I n v e
r o p o s a l
on of extrac
g and Heart
IMA
t global hea
the‐art ther
e in the my
hypertroph
ve depositio
tients with
This increa
iffness and
e s t i g a c i
E d i t i o n
cellular mat
Failure.
alth proble
rapy and an
yocardium i
hy of the c
on of collage
HF and als
sed collage
can lead to
ó n B i o m
2 0 1 4 ‐ 2
trix quantity
m, with hig
n increasing
n HF, know
ardiomyocy
en or fibros
o in associa
en depositio
myocardia
é d i c a
0 1 5
y and qualit
gh socio‐san
prevalence
wn as myoca
ytes, a dec
sis.
ated pathol
on has a cl
l dysfunctio
ty
nitary
e.
ardial
rease
logies
linical
on.
But n
struc
form
alter
Reac
fibro
mess
prod
Amo
ROS
to m
quali
The g
and q
ELISA
REFE
1
2
3
M á s t e
R e s
not only co
cture and
mation of co
red in HF.
ctive oxyge
osis, both d
sengers an
uction.
ngst ROS s
production
myocardial f
ity remains
goal of the
quality, usin
A and cell cu
ERENCES
1. Mechan
hypertro
Querejet
2. Collagen
pressure
lysyl ox
Hyperte
3. Blockade
hyperten
e r U n i v e
e a r c h P
ollagen qua
function. T
ollagen fibe
n species
due to thei
nd because
ources, the
n. The NADP
fibrosis, alth
to be elucid
project is t
ng molecula
ulture.
isms of dise
ophy in hy
ta R. Nat Cl
n cross‐linki
es in hypert
xidase. Lóp
nsion. 2012
e of TGF‐β
nsive rats.
e r s i t a r i o
r o j e c t P
ntity but a
The proces
rs and thei
(ROS) can
r regulatio
e their acc
e NADPH ox
PH oxidases
hough their
dated.
to study ho
ar biology t
ease: patho
ypertensive
in Pract Car
ng but not
tensive pati
pez B, Qu
2;60:677‐83
1 signalling
Miguel‐Car
o e n I n v e
r o p o s a l
lso its qual
ss of synth
r degradati
regulate c
n of collag
cumulation,
xidase is th
s are expre
r effect on
ow the NAD
echniques i
ologic struct
heart dis
rdiovasc Me
collagen a
ients with s
uerejeta R,
3.
g inhibits c
rrasco JL,
e s t i g a c i
E d i t i o n
lity (ie, stiff
hesis of th
ion is orche
cellular ho
gen synthes
, oxidative
e only enzy
essed in the
the regula
DPH oxidase
including Re
tural remod
ease. Díez
ed. 2005;2:2
mount asso
stage C hea
, González
cardiac NAD
Baltanás A
ó n B i o m
2 0 1 4 ‐ 2
fness) can a
he collagen
estrated by
meostasis
sis in their
e stress, in
yme whose
e heart and
ation collag
es modify c
eal time PC
eling is mo
J, Gonzál
209‐16.
ociates with
art failure: p
z A, Larm
DPH oxidase
, Cebrián C
é d i c a
0 1 5
alter myoca
n molecule
y enzymes a
and myoca
role as se
nduces col
e inherent r
d may contr
en quantity
collagen qua
CR, Western
re than ada
ez A, Lópe
h elevated
potential ro
an M, Dí
e overactiv
C, Moreno
ardial
, the
and is
ardial
econd
lagen
role is
ribute
y and
antity
n blot,
aptive
ez B,
filling
ole of
ez J.
vity in
MU,
POSS
Yes
M á s t e
R e s
López B,
Zalba G.
SIBILITY OF
e r U n i v e
e a r c h P
, Hermida N
Oxid Med C
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
N, González
Cell Longev
/NO)
o e n I n v e
r o p o s a l
z A, Dotor
. 2012;2012
e s t i g a c i
E d i t i o n
J, Borrás‐C
2:726940.
ó n B i o m
2 0 1 4 ‐ 2
uesta F, Dí
é d i c a
0 1 5
íez J, Fortuño A,
PROJ
Mech
Alzhe
DEPA
Depa
.
DIRE
Marí
CONT
mari
SUM
Cogn
near
thera
norm
effec
grad
ident
key
resis
and n
M á s t e
R e s
JECT 16
hanisms in
eimer´s dise
ARTAMENT/
artment of .
CTOR
ía Javier Ram
TACT
MMARY
nitive defici
ly 50% of a
apeutic inte
mal and pat
cts at the
ually expan
tification of
componen
tance such
neural defic
e r U n i v e
e a r c h P
nvolved in
ease
/LABORATO
.Pharmacol
mírez and M
es, 9484256
ts has eme
adults over
erventions
hological b
cellular an
nded, from i
f a role in re
t of hippo
as that see
cits in clinic
e r s i t a r i o
r o j e c t P
cognitive
ORY
ogy and Tox
Maite Solas.
600, ext 806
erged as on
the age of
demands a
rain ageing
d organism
initial conce
egulation o
ocampal m
en in type 2
al, epidemio
o e n I n v e
r o p o s a l
deficits a
xicology, Un
.
6261.
e of the gr
85 afflicted
a deep kno
g. Insulin is
mal levels.
eptions of t
of feeding, t
emory pro
2 diabetes i
ological and
e s t i g a c i
E d i t i o n
associated
nav
reatest heal
d with Alzhe
owledge of
a pleiotrop
The role o
the brain as
o recent de
ocesses. Co
is associate
d experime
ó n B i o m
2 0 1 4 ‐ 2
to insulin
lth threats
eimer's dise
f the proce
ic hormone
of insulin in
s insulin‐ins
emonstratio
onversely, s
d with a ra
ntal studies
é d i c a
0 1 5
n resistanc
of old age,
ease. Develo
esses unde
e with nume
n the brain
ensitive thr
on of insulin
systemic in
ange of cog
s. In fact, ins
ce in
, with
oping
rlying
erous
n has
rough
n as a
nsulin
nitive
sulin‐
resis
to st
situa
used
mod
path
bioch
POSS
Yes
M á s t e
R e s
tance is a w
udy the bio
ations of ins
d: high fat
els, in add
ology, it
hemical me
SIBILITY OF
e r U n i v e
e a r c h P
well‐known
ochemical m
sulin resista
diet fed a
dition to ch
will be st
echanisms th
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
risk factor
mechanisms
ance. Two e
animals and
heck cognit
tudied ins
hat could b
/NO)
o e n I n v e
r o p o s a l
for Alzheim
s that could
experiment
d stress‐ind
tive status
sulin‐resista
e involved.
e s t i g a c i
E d i t i o n
mer´s diseas
be respons
tal models o
duced insu
and marke
nce, insul
ó n B i o m
2 0 1 4 ‐ 2
e. In this w
sible for cog
of insulin‐re
lin‐resistan
ers of Alzh
in‐related
é d i c a
0 1 5
work it is pla
gnitive defic
esistance w
ce. In all
heimer´s di
pathways,
anned
cits in
will be
these
sease
and
PROJ
New
patie
DEPA
Labo
Scien
DIRE
Aran
Co‐d
CONT
e‐ma
Phon
SUM
Hear
mort
with
rate
are n
the o
One
myoc
M á s t e
R e s
JECT 17
therapeut
ents
ARTAMENT/
oratories of
nces, CIMA
CTOR
txa Gonzále
irector: Beg
TACT
ail: amiqueo
ne: Ext (81)‐
MMARY
rt failure (H
tality and h
the optima
below 40%
not effectiv
onset and p
of the ma
cardial fibro
e r U n i v e
e a r c h P
tic targets
/LABORATO
Myocardia
ez Miqueo
goña López
‐3023
HF) is a com
ospitalizatio
al pharmaco
% 5 years af
ve enough.
rogression
in histopat
osis, which
e r s i t a r i o
r o j e c t P
for the tre
ORY
al Remodeli
Salazar
mplex syndr
ons in West
ological trea
ter diagnos
Therefore
of this disea
thological a
increases le
o e n I n v e
r o p o s a l
eatment of
ing and He
rome repre
tern countr
atment, the
sis, suggesti
it is essent
ase.1
alterations
eft ventricu
e s t i g a c i
E d i t i o n
f myocardi
art Failure,
esenting on
ries includin
e prognosis
ing that the
ial to ident
underlying
lar stiffness
ó n B i o m
2 0 1 4 ‐ 2
al fibrosis
Division o
ne of the le
ng Spain. Im
is very bad
e agents cu
ify new tar
the develo
s contributin
é d i c a
0 1 5
in heart fa
of Cardiovas
eading caus
mportantly,
d, with a su
urrently ava
rgets involv
opment of
ng to the
ailure
scular
ses of
even
rvival
ilable
ved in
HF is
impa
colla
proce
such
osteo
our g
deve
that
In th
vivo
osteo
inter
mole
Selec
1‐ Go
remo
2‐ Ló
cardi
Hype
3‐ Ló
Zuda
med
2013
M á s t e
R e s
airment of c
gen fibers
ess is regul
as cytoki
opontin) an
group has
elopment of
osteoponti
is conceptu
the role of
opontin; 2)
rference RN
ecules) or ap
cted referen
onzález A, R
odeling of th
ópez B, Go
iotrophin‐1
ertension 20
ópez B, Gon
aire A, Brug
iated myoc
3;99:111‐12
e r U n i v e
e a r c h P
cardiac func
due to an
lated by a
ines (e.g.
nd oxidative
recently sh
f myocardia
n is involve
ual framewo
f newly iden
To develop
NA, peptid
ptamers de
nces from t
Ravassa S, B
he myocard
onzález A, Q
with myoc
014;63:483
nzález A, Li
gnolaro C,
cardial fibro
20.
e r s i t a r i o
r o j e c t P
ction. This f
imbalance
number of
TGF‐β and
e stress (e.g
hown that c
al fibrosis in
d in the pro
ork this proj
ntified play
p and test i
des, chemic
pending on
he group on
Beaumont J
dium. J Am C
Querejeta R
cardial fibro
‐489.
ndner D, W
Querejeta
osis in heart
o e n I n v e
r o p o s a l
fibrosis is th
between i
factors wh
d cardiotro
g. NADPH ox
cardiotroph
n these pat
ocess of col
ject has 2 o
yers in myo
nhibitors fo
cal inhibito
n the target
n the topic
J, López B,
Coll Cardiol
R, Larman
osis in hyp
Westermann
R, Larman
t failure. A
e s t i g a c i
E d i t i o n
he result of
ts synthesis
hich are ove
ophin‐1), m
xidases [NO
hin‐1 may p
tients.2 Sim
lagen cross
objectives: 1
cardial fibr
or the most
ors (screen
.
Díez J. New
l 2011;58:18
M, Rábago
pertensive p
n D, Ravass
M, Tschöp
role for lys
ó n B i o m
2 0 1 4 ‐ 2
f an excessi
s and its d
er‐expresse
matricellular
OX]‐mediate
play a relev
milarly, we h
‐linking.3
1) To validat
osis like ca
promising
ning of lib
w targets to
833‐1843.
o G, Díez J
patients wit
a S, Beaum
pe C, Díez
syl oxidase?
é d i c a
0 1 5
ive depositi
egradation
d in HF pat
r proteins
ed). In parti
vant role i
have also s
te in vitro a
rdiotrophin
targets by
braries of
o treat struc
J. Associatio
th heart fa
mont J, Galle
J. Osteopo
? Cardiovas
on of
. This
tients
(e.g.
cular,
n the
hown
and in
n‐1 or
using
small
ctural
on of
ailure.
ego I,
ontin‐
sc Res
POSS
YES
M á s t e
R e s
SIBILITY OF
e r U n i v e
e a r c h P
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
/NO)
o e n I n v e
r o p o s a l
e s t i g a c i
E d i t i o n
ó n B i o m
2 0 1 4 ‐ 2
é d i c a
0 1 5
PROJ
DISSE
DEPA
Adhe
Divis
CIMA
DIRE
Fern
CONT
fleca
948 1
SUM
Meta
host
proce
(Antó
enga
for th
MiRN
mult
cont
M á s t e
R e s
JECT 18
ECTING MU
ARTAMENT/
esion and M
sion of Onco
A
CTOR
ando LECAN
TACT
anda@unav
194 700 Ext
MMARY
astasis is a
tissues, as
ess, cell–ce
ón et al. A
agement in
hriving effic
NAs are no
istep proce
rol basic ce
e r U n i v e
e a r c h P
ULTIGENIC m
/LABORATO
Metastasis L
ology
NDA
.es
t 1001
multistep p
“the seed
ell and cell–
Am J Resp
host tissue
ciently in th
on coding R
ess. They all
llular functi
e r s i t a r i o
r o j e c t P
miRNAs‐DRI
ORY
aboratory
process that
in a fertile
–matrix rec
p Care Med
(Catena et
e target org
RNAs which
ow postran
ions such as
o e n I n v e
r o p o s a l
IVEN NETW
t requires c
soil”. We h
ceptors are
d 2012) (V
al. Canc Re
gan (Luis‐Ra
h are impli
nscriptional
s proliferati
e s t i g a c i
E d i t i o n
WORKS IN M
compatibilit
have previo
crucial for
Valencia et
es 2010), an
avelo et al.
icated in se
regulation
ion, differen
ó n B i o m
2 0 1 4 ‐ 2
ETASTASIS
ty between
usly shown
r survival in
al. 2012
nd other fun
Oncogene 2
everal mec
of multigen
ntiation and
é d i c a
0 1 5
tumor cell
that durin
n the circul
Clin Canc
nctions req
2013)
chanisms o
nic network
d apoptosis
s and
g this
lation
Res),
quired
f this
ks and
. We
have
as su
relea
the e
Rece
assoc
down
the m
mod
To va
1) To
dysre
overe
mou
throu
2) To
miRN
meta
be su
targe
POSS
YES
M á s t e
R e s
e recently sh
urrogate bio
ased by tum
efficient col
ently, in hu
ciated with
nstream ta
metastatic
alities.
alidate this
o identify
egulation o
expression
se and xen
ugh system
o mechanist
NAs by me
astasis repr
ubsequentl
ets to block
SIBILITY OF
e r U n i v e
e a r c h P
hown that c
omarkers (V
mor cells in
onization o
man lung c
h adverse
rgets, could
cascade th
hypothesis
and functi
of key m
and silenc
ograft mod
s biology an
tically disse
eans of com
oducing the
y validated
this detrim
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
circulating m
Valencia et
exosome‐li
f the target
cancer pati
outcome.
d lead to th
at could be
the followi
onally char
iRNAs usin
cing, in vit
dels, compu
nd function
ect the regu
mputationa
e aggressive
in human
mental proce
/NO)
o e n I n v e
r o p o s a l
miRNAs rele
t al. Bone 2
ike vesicles
t organ (Val
ients, our l
We hypo
he discovery
e useful in
ing specific
racterize ro
ng a mult
tro cell cul
utational m
al genomics
ulatory gene
al tools tak
e lesions ob
samples. T
ess.
e s t i g a c i
E d i t i o n
eased durin
2012). More
s to the sur
encia et al.
laboratory
othesize th
y of novel
the design
aims are su
obust gene
tipronged
lture mode
odeling, dis
s).
e network m
ken advant
bserved in h
This strateg
ó n B i o m
2 0 1 4 ‐ 2
ng metastas
eover, miRN
rounding m
Mol Onc 20
has identif
hat identifi
molecular v
n of innova
uggested:
networks
approach
els, genetic
ssection of
modulated b
tage of mu
humans. Th
y will unve
é d i c a
0 1 5
sis could be
NAs can als
milieu, leadi
014).
fied key mi
cation of
vulnerabilit
ative therap
elicited by
(including
cally engine
signaling e
by the iden
urine mode
hese finding
eil potential
used
so be
ng to
RNAs
their
ies of
peutic
y the
viral
eered
vents
ntified
els of
gs will
l new
PROJ
Alph
DEPA
Cellu
DIRE
Mon
CONT
emai
SUM
Shor
goals
than
Abno
neur
othe
dupli
Parki
facto
selec
Aim:
neur
M á s t e
R e s
JECT 19
a synuclein
ARTAMENT/
ular Neurob
CTOR
tserrat Arra
TACT
il: marrasat
MMARY
t summary
s and the m
three).
ormal accu
rodegenerat
rs, comm
ications/trip
inson’s dise
or of neuro
cted neuron
We se
rodegenerat
e r U n i v e
e a r c h P
‐dependent
/LABORATO
iology labo
asate, Ph.D.
of the proj
methodolog
mulation o
tive disorde
monly kn
plications o
ease, point
onal death.
nal populati
eek to i
tion. Specif
e r s i t a r i o
r o j e c t P
t mechanism
ORY
ratory (2.05
.
s Phone Nu
ject with a
gy that will
of alpha‐syn
ers like Park
nown as
of the alp
ting toward
Yet, how
ons affecte
identify a
ically; we w
o e n I n v e
r o p o s a l
ms of neuro
5), Neurosc
mber: 9481
maximum
be used.
nuclein into
kinson’s dis
synucleo
pha‐synucle
ds alpha‐sy
alpha‐synu
ed on these
alpha‐synuc
want to dete
e s t i g a c i
E d i t i o n
odegenerat
iences Depa
194700 Ext:
extension o
References
o Lewy Bod
sease, deme
opathies.
in gene ca
nuclein cel
clein is cau
disorders is
clein depe
ermine if/ho
ó n B i o m
2 0 1 4 ‐ 2
ion.
artment‐CIM
2008
of 250 word
could be a
dies (LBs) i
entia with L
Point m
ause autos
lular levels
usally tied
s unknown.
endent m
ow the expr
é d i c a
0 1 5
MA
ds, includin
added (no
is a hallma
Lewy Bodie
mutations
somal dom
s as a caus
to the dea
.
mechanisms
ression of w
ng the
more
ark of
s and
and
minant
sative
ath of
s of
wild‐
type
mod
Meth
neur
inter
name
are a
longi
wild‐
neur
and t
1.
2.
M á s t e
R e s
and diffe
ifications af
hodology: W
rons over lo
rest (i.e. ex
ed longitud
able to link
itudinal sur
‐type and
ronal popula
transfection
Tsvetkov A
Finkbeiner
predicts ne
Miller* J.,
Cheung K.
Mitcell E.,
M., Yang W
Finkbeiner
predict n
contributio
e r U n i v e
e a r c h P
erent mut
ffects the su
We have es
ong periods
xpression le
dinal surviva
the appear
rvival analy
mutant ver
ations. The
n of primary
AS., Arrasat
r S. (2013)
eurodegene
Arrasate* M
., Krishnan
Osmand A
W.X., Maslia
r S. (2011)
eurodegene
on)
e r s i t a r i o
r o j e c t P
ant versio
urvival of di
stablished a
s of time th
evels, prote
al analysis‐
rance of a p
ysis we wil
rsions of a
project req
y neurons, m
te M., Barm
Proteostas
eration. Nat
M., Brooks E
P., Mitra S
., Gray M.,
ah E., Thom
Identifying
eration. Na
o e n I n v e
r o p o s a l
ons of alp
ifferent neu
a microsco
hat simultan
in turnover
and obser
particular fe
l determine
alpha‐synuc
quires mole
microscopy
mada S., An
sis of polyg
ture Chemi
E., Peters‐Li
S., Widjaja
Thulasiram
mpson L.M.,
polyglutam
ature Chem
e s t i g a c i
E d i t i o n
pha‐synucle
uronal popu
py based‐s
neously ena
r) and surv
rving the sa
eature with
e if/how th
lein affects
ecular biolo
y and statist
ndo M.D., S
glutamine v
cal Biology,
ibeu C., Leg
K., Shaby B
min V., Saud
Muchowsk
mine protei
mical Biolo
ó n B i o m
2 0 1 4 ‐ 2
in and po
ulations.
ystem to fo
ables to mo
ival. Using
ame neuron
h its ultimat
he transien
s the survi
gy techniqu
ics.
Sharma P.,
varies amo
Sep;9(9):58
leiter J., Hat
B.A., Lotz G
ou F, Much
ki P.J., Weisg
in species i
ogy. 7(12):9
é d i c a
0 1 5
ost‐translat
follow indiv
onitor even
this appro
n repeatedl
te fate. By
nt expressio
val of diffe
ues, prepar
Shaby B.A.
ng neurons
86‐92.
tters D., Cu
.P.Newhou
howski P.J.,
graber K. H
in situ that
925‐34. (*
tional
vidual
nts of
ach ‐
y we
using
on of
erent
ation
., and
s and
rtis J.,
se Y.,
Segal
., and
t best
equal
3.
POSS
I wou
of th
M á s t e
R e s
Arrasate
determinin
(10) 3840‐
SIBILITY OF
uld like the
e fellow an
e r U n i v e
e a r c h P
M. and Fi
ng factors
‐5.
Ph.D. (YES/
project to b
d the availa
e r s i t a r i o
r o j e c t P
inkbeiner S
that predic
/NO)
be continue
able financia
o e n I n v e
r o p o s a l
S. (2005).
ct neuronal
ed with a Ph
al support a
e s t i g a c i
E d i t i o n
Automate
fate. Proc
h.D. It will d
at the mom
ó n B i o m
2 0 1 4 ‐ 2
d microsco
. Natl. Acad
depend on t
ent.
é d i c a
0 1 5
ope system
d. Sci. USA
the perform
m for
A, 102
mance
PROJ
Char
DEPA
Micr
CIMA
DIRE
Direc
Co‐d
CONT
Dr. P
SUM
Leish
cause
effec
mana
treat
strat
comp
biolo
thera
M á s t e
R e s
JECT 20
racterization
ARTMENT/L
obiology an
A. Lab 2.03
CTOR
ctor: Dr. Pau
irector: Dra
TACT
Paul Nguewa
MMARY
hmaniasis is
ed by the
ctive vacci
agement o
tment by c
egies is red
plete genom
ogy of thes
apeutic targ
e r U n i v e
e a r c h P
n of the hom
LABORATOR
nd Parasitol
ul Nguewa.
a. Celia Fern
a: panguew
s one of th
protozoan
ne, curren
of vector a
chemothera
duced by gr
me sequen
e parasites
gets and bio
e r s i t a r i o
r o j e c t P
molog of th
RY
ogy Depart
nández Rub
he 17 negle
parasites o
nt approac
nd reservo
apeutic age
rowing incid
ce of Leish
s offer new
omarkers, a
o e n I n v e
r o p o s a l
e oncogene
tment. Rese
io
s 806434 (D
ected tropic
of the genu
ches of d
oir hosts in
ents. Howe
dences of d
mania spp.
w directions
nd for the d
e s t i g a c i
E d i t i o n
e Pes in Leis
earch Buildi
Dept.) /8120
cal disease
us Leishma
isease con
n order to
ever, efficie
drug resista
and the b
s for resear
design of no
ó n B i o m
2 0 1 4 ‐ 2
shmania ma
ng.
019 (CIMA)
s recognize
nia. Due to
ntrol are
reduce tra
ency of cu
ance. The av
etter unde
rch in the
ovel treatm
é d i c a
0 1 5
ajor.
ed by the W
o the lack
limited to
ansmission,
rrent treat
vailability o
rstanding o
identificatio
ent strateg
WHO,
of an
o the
, and
tment
of the
of the
on of
ies.
Rece
targe
exhib
milte
the
proli
infec
studi
comm
the p
and
chara
1
2
3
POSS
Indic
Yes (
M á s t e
R e s
ent studies
ets. Various
bit leishma
efosine and
proliferatio
feration of
ctions like s
ies in the f
monly invol
presence of
we would
acterization
1. A. C. Iven
2. W. Xie e
3. L. Cheng
SIBILITY OF
cate if the p
to be discu
e r U n i v e
e a r c h P
have ident
s drugs, init
nicidal acti
d edelfosine
on of Lei
cancer cells
schistosomi
field are lik
lved in both
f the homo
d like to
n of this gen
ns et al., Sc
t al., PLoS.O
g et al., J.Clin
Ph.D. (YES/
roject could
ssed).
e r s i t a r i o
r o j e c t P
tified, in bo
ially design
vity, with s
e). It has al
shmanias
s. Furtherm
asis, have a
kely to be d
h infectious
olog of the
propose t
ne in Leishm
ience 309, 4
One. 7, e422
n.Invest 122
/NO)
d be continu
o e n I n v e
r o p o s a l
oth tumor
ed as antitu
some of th
so been ob
inside ma
more, many
also been d
directed to
s diseases an
oncogene
the structu
mania major
436‐442 (20
253 (2012).
2, 2857‐287
ued with a
e s t i g a c i
E d i t i o n
cells and p
umor agent
hem already
bserved tha
acrophages
infectious d
demonstrate
wards the
nd cancer. W
Pes in the
ural, funct
r.
005).
70 (2012).
Ph. D. (doct
ó n B i o m
2 0 1 4 ‐ 2
parasites, si
ts, have bee
y in use in
at certain c
resemble
diseases, in
ed to be on
identificatio
We have re
genome of
ional, and
toral thesis)
é d i c a
0 1 5
imilar mole
en shown to
the clinic
characterist
those of
ncluding par
ncogenic. F
on of mole
ecently iden
f Leishmani
immunolo
)
ecular
o also
(e.g.,
ics of
f the
rasitic
uture
ecules
ntified
a spp
ogical
PROJ
Regu
DEPA
Unfo
Prog
DIRE
Tomá
CONT
emai
SUM
Shor
goals
than
The
intra
foldi
indep
prog
At its
of th
M á s t e
R e s
JECT 21
ulation of XB
ARTAMENT/
olded prote
ram (4.02‐T
CTOR
ás Aragón,
TACT
il: taragon@
MMARY
t summary
s and the m
three).
unfolded p
cellular sign
ng within t
pendent se
ram to upg
s most cons
e mRNA en
e r U n i v e
e a r c h P
BP1 splicing
/LABORATO
in response
T) ‐ CIMA
Ph.D.
@gmail.com
of the proj
methodolog
protein res
naling pathw
the ER cau
ensors that
rade ER size
served bran
ncoding the
e r s i t a r i o
r o j e c t P
g in respons
ORY
e laboratory
m Phone Num
ject with a
gy that will
ponse (UP
way that en
use a situa
, in turn, p
e and funct
nch, the UP
transcriptio
o e n I n v e
r o p o s a l
se to endop
y, Gene The
mber: 9481
maximum
be used.
R) is an en
nsures ER h
tion known
promote th
ional capac
R sensor Ire
on factor XB
e s t i g a c i
E d i t i o n
lasmic retic
erapy and G
194700 Ext:4
extension o
References
ndoplasmic
omeostasis
n as ER str
he establish
city and alle
e1 catalyzes
BP1. This sp
ó n B i o m
2 0 1 4 ‐ 2
culum stress
Gene Expres
4019
of 250 word
could be a
reticulum
. Deficienci
ress which
hment of a
viate stress
s the non‐ca
plicing react
é d i c a
0 1 5
s.
ssion Regul
ds, includin
added (no
(ER)‐to‐nu
es in the pr
activates
a transcript
s.
anonical sp
tion occurs
lation
ng the
more
ucleus
rotein
three
tional
plicing
at ER
stres
these
num
targe
XBP1
exist
targe
Aim:
Spec
traje
Meth
ident
valid
cells,
prev
1.
POSS
Indic
This
on 1
supp
M á s t e
R e s
ss signaling
e splicing c
ber of phys
eting of XBP
1 to the E
ence of a
eting eleme
Here, we
cifically, we
ctory and s
hodology: W
tify bound
ate the hit
, we will tak
iously.
Aragón T,
P. (2009)
sites. Natu
SIBILITY OF
cate if the p
project is s
) the qualif
port the pro
e r U n i v e
e a r c h P
centers in
enters is ke
siopatholog
P1 mRNA t
R. Our gro
different t
ents (XBP1 s
e aim to
e will iden
peed of XB
We will perf
factors by
ts of this se
ke advantag
van Anken
Messenger
ure;457(723
Ph.D. (YES/
roject could
uited to be
fication of t
oject.
e r s i t a r i o
r o j e c t P
the cytosol
ey to ensur
gical situatio
o these cen
oup has ob
transport m
splicing elem
understand
tify XSE‐as
P1 transpor
form affinit
mass spect
earch. To v
ge of in vivo
E, Pincus D
r RNA targe
30):736‐40.
/NO) YES
d be continu
expanded
the student
o e n I n v e
r o p o s a l
lic surface o
re the surv
ons. A mod
nters, base
btained com
mechanism
ments, XSEs
d the mec
ssociated f
rt.
ty purificati
trometry. F
visualize the
o visualizat
, Serafimov
eting to en
ued with a
in a PhD th
t and 2) th
e s t i g a c i
E d i t i o n
of the ER(1
ival of cells
del has bee
d on the co
mpelling ev
in human
s) and does
chanism o
factors, and
on experim
Functional e
e movemen
ion constru
va IM, Koren
ndoplasmic
Ph. D. (doct
esis. The de
e availabilit
ó n B i o m
2 0 1 4 ‐ 2
). XBP1 mR
s under ER
en proposed
o‐translatio
vidence dem
cells, whic
not require
f XBP1 m
d we will
ments using
experiment
nt of XBP1
cts generat
nnykh AV, R
reticulum
toral thesis)
ecision to d
ty of financ
é d i c a
0 1 5
RNA transpo
stress in a
d to explai
onal transpo
monstrating
ch utilizes
e translation
RNA trans
determine
XSEs as ba
ts will be u
mRNA in
ted in our g
Rubio CA, W
stress sign
)
o so will de
cial resourc
ort to
wide
n the
ort of
g the
novel
n.
sport.
e the
ait, to
se to
living
group
Walter
alling
epend
ces to
PROJ
Deve
gene
DEPA
Depa
DIRE
Crist
CONT
csme
tel. 9
SUM
In ou
vecto
Rece
antib
of im
Thes
In t
imm
that
M á s t e
R e s
JECT 22
elopment of
e therapy
ARTAMENT/
artment of G
CTOR
ian Smerdo
TACT
erdou@una
948194700
MMARY
ur laborato
ors express
ently it has
bodies able
mmune resp
e antibodie
the presen
unomodula
purpose th
e r U n i v e
e a r c h P
f viral vecto
/LABORATO
Gene Thera
ou
av.es
ext. 4027
ory we hav
ing immuno
been show
to either s
ponses.
es have bee
nt project
atory antibo
e following
e r s i t a r i o
r o j e c t P
ors able to e
ORY
apy, CIMA
ve extensiv
ostimulator
wn that th
timulate ac
n successfu
we prop
odies by usi
partial obje
o e n I n v e
r o p o s a l
express imm
vely worked
ry molecule
he immune
ctivators of
ully used in c
pose to
ing viral vec
ectives are
e s t i g a c i
E d i t i o n
munomodu
d in cancer
s, like cytok
system ca
immune re
clinical trial
test a ne
ctors able t
proposed:
ó n B i o m
2 0 1 4 ‐ 2
latory antib
r gene the
kines.
an be mod
esponses or
s involving
ew approa
o express t
é d i c a
0 1 5
bodies for c
erapy using
dulated by
r block inhib
cancer pati
ach to d
them in vivo
ancer
viral
using
bitors
ients.
eliver
o. For
‐ Con
with
‐ Tes
‐ Tes
The
Biolo
canc
POSS
The p
fellow
M á s t e
R e s
nstruction a
antitumor
sting expres
sting the ant
project wil
ogy, cell cult
er etc.
SIBILITY OF
project cou
wship.
e r U n i v e
e a r c h P
and product
properties.
ssion of the
titumoral a
ll involve t
ture, virus p
Ph.D. (YES/
ld be conti
e r s i t a r i o
r o j e c t P
tion of a vi
antibody in
ctivity of th
the use of
production,
/NO)
nued with a
o e n I n v e
r o p o s a l
ral vector a
n vitro.
his vector in
many diffe
, analysis of
a Ph. D. pro
e s t i g a c i
E d i t i o n
able to expr
animal mo
erent techn
f protein ex
ovided that
ó n B i o m
2 0 1 4 ‐ 2
ress a mono
dels of canc
niques inclu
xpression, a
the candid
é d i c a
0 1 5
oclonal ant
cer.
uding Mole
animal mod
date can obt
ibody
ecular
els of
tain a
PROJ
The F
DEPA
Labo
CIMA
Depa
DIRE
Albe
CONT
lame
TF. 9
SUM
The f
recep
actio
foun
hippo
these
them
thera
M á s t e
R e s
JECT 23
Free Fatty A
ARTAMENT/
oratory of C
A
artment of B
CTOR
rto Pérez‐M
TACT
ediav@unav
948194700 e
MMARY
free fatty ac
ptors have
on of the
d the exis
ocampus of
e receptors
m to act as
apeutic stra
e r U n i v e
e a r c h P
Acids Recep
/LABORATO
Cellular and
Biochemistr
Mediavilla
v.es
ext 2033
cid recepto
as natural a
bacterial flo
stence of
f patients w
s induce th
s memory
ategies for A
e r s i t a r i o
r o j e c t P
ptors as new
ORY
Molecular
ry and Gene
rs are a rec
agonists sh
ora on the
changes i
with Alzheim
e activation
inducers a
Alzheimer’s
o e n I n v e
r o p o s a l
w targets fo
r Neuropha
etics. Schoo
cently discov
ort fatty ac
diet’s fibe
n the exp
mer (1); we
n of the pC
nd makes
Disease.
e s t i g a c i
E d i t i o n
r Alzheimer
rmacology.
ol of Science
vered group
cids produce
er content.
pression of
e have also
CREB pathw
them targe
ó n B i o m
2 0 1 4 ‐ 2
r’s Disease t
Division of
es.
p of the GP
ed mostly a
In recent s
f these re
found that
way which g
ets for the
é d i c a
0 1 5
therapies
f Neuroscie
CR family. T
as a result o
studies we
eceptors in
t the agoni
give us the
e design of
ences.
These
of the
have
n the
sts of
e idea
f new
(
POSS
If the
by a
M á s t e
R e s
1) Zama
MS,
CREB
mou
doi:
SIBILITY OF
e work of th
PhD
e r U n i v e
e a r c h P
arbide M1,
Luis Lancieg
B and ERK
se CNS and
10.1002/hip
Ph.D. (YES/
he Master’s
e r s i t a r i o
r o j e c t P
Etayo‐Labi
go J, Pérez‐
phosphory
d in human
po.22263. [
/NO)
s degree stu
o e n I n v e
r o p o s a l
ano I, Ricob
‐Mediavilla
ylation in p
neuroblasto
Epub ahead
udent is sat
e s t i g a c i
E d i t i o n
baraza A, M
A, Franco R
rimary cult
oma cells. H
d of print]
tisfactory, t
ó n B i o m
2 0 1 4 ‐ 2
Martínez‐Pin
R. GPR40 ac
tures of ne
Hippocamp
his project
é d i c a
0 1 5
nilla E, Aym
ctivation lea
eurons from
us. 2014 Fe
will be foll
merich
ads to
m the
eb 18.
owed
PROJ
lncRN
Proje
DEPA
Labo
CUN,
DIRE
Nam
CONT
Cont
SUM
Shor
goals
than
Most
such
Rece
are e
prog
RNAs
M á s t e
R e s
JECT 24
NAs in disea
ect title
ARTAMENT/
oratory whe
, CIMA etc.
CTOR Puri F
e and surna
TACT pforte
tact e‐mail a
MMARY
t summary
s and the m
three).
t of the ge
as ribosom
ently, the an
essential fo
nosis and t
s (lncRNAs)
e r U n i v e
e a r c h P
ase
/LABORATO
ere the proj
Fortes
ame of the
and phone n
of the proj
methodolog
enome is tr
mal or tRN
nalysis of sh
or cell home
herapy of c
could be as
e r s i t a r i o
r o j e c t P
ORY. Lab 40
ect will be
director. If
s
number.
ject with a
gy that will
ranscribed i
NA, have be
hort ncRNAs
eostasis. Fu
certain dise
s relevant a
o e n I n v e
r o p o s a l
6. Gene the
carried out
there will b
maximum
be used.
into non‐co
een studied
s or microR
urthermore,
eases. In ou
as miRNAs. W
e s t i g a c i
E d i t i o n
erapy depar
t indicating
be two co‐d
extension o
References
oding RNAs
d for deca
RNAs (miRNA
, miRNAs a
r lab, we be
We have id
ó n B i o m
2 0 1 4 ‐ 2
rtment. CIM
Departmen
irectors ind
of 250 word
could be a
s (ncRNAs).
des. Other
As) have re
re useful fo
elieve that
entified lnc
é d i c a
0 1 5
MA
nt, Area, Fa
dicate both.
ds, includin
added (no
Some of t
rs are unkn
evealed that
or the diagn
long non‐co
cRNAs whos
culty,
ng the
more
them,
nown.
t they
nosis,
oding
se
expre
proje
lncRN
cons
miRN
resul
hybr
polya
overe
repli
help
POSS
Indic
M á s t e
R e s
ession is alt
ect of the
NAs. To th
ervation, st
NA binding
lts will be v
idization a
adenylation
expression
cons will be
for the iden
SIBILITY OF
cate if the p
e r U n i v e
e a r c h P
tered upon
master stu
his aim the
tructure an
sites and e
validated e
and quant
n status. Fin
in the IFN
e used to av
ntification o
Ph.D. (YES/
roject could
e r s i t a r i o
r o j e c t P
n HCV infect
udent will b
e student
nd expressio
epigenetic m
xperimenta
titative RT
nally, the ln
response
void the ris
of lncRNAs o
/NO) Depen
d be continu
o e n I n v e
r o p o s a l
tion or HCV
be to analy
will perfor
on (ie. sea
modification
ally. Experim
T‐PCR to
ncRNA will
or HCV re
k of HCV in
of therapeu
nds on fundi
ued with a
e s t i g a c i
E d i t i o n
V treatment
yze the fun
rm bioinfor
rch for put
ns that affe
ments will
describe
be cloned
plication. T
fections. W
utic interest
ing
Ph. D. (doct
ó n B i o m
2 0 1 4 ‐ 2
t with inter
nctionality
rmatic ana
tative trans
ect lncRNA e
be perform
lncRNA lo
to determi
To this aim
We hope tha
t.
toral thesis)
é d i c a
0 1 5
rferon (IFN)
of two rele
alysis of ln
scription fa
expression)
med using in
ocalization
ine the effe
safe replic
at the result
)
). The
evant
cRNA
ctors,
). The
n situ
and
ect of
cative
ts will
PROJ
Role
DEPA
Area
DIRE
Dr. S
CONT
sroa@
SUM
The
respo
unde
auto
mech
unde
work
demo
a sub
appe
have
B‐cel
M á s t e
R e s
JECT 25
of the tran
ARTAMENT/
of Hemato
CTOR
ergio Roa G
TACT
@unav.es (x
MMARY
germinal c
onses and i
erlying mo
immune di
hanisms co
erstanding n
k on FOXP1
onstrated t
bset of diff
ears to be l
e an additive
ll type (ABC
e r U n i v e
e a r c h P
scription fa
/LABORATO
ological Onc
Gómez (Mar
x1028)
center (GC
s necessary
lecular pro
sorders and
ntrolling th
normal ada
1 (Forkhead
to be down
fuse large
inked to th
e adverse ro
C) DLBCLs w
e r s i t a r i o
r o j e c t P
ctor FOXP1
ORY
cology / Mo
rie Curie IIF
C) reaction
y for immun
ocesses ma
d lymphom
is unique im
ptive immu
d box‐P1), a
regulated in
B‐cell lymp
e GC reacti
ole in the p
ith worse p
o e n I n v e
r o p o s a l
1 in B cell fu
lecular Onc
‐Fellow)
is a hallm
ne defense.
ay predispo
ma. Consequ
mmune rea
unity and lym
a winged‐h
n GC lymph
phomas (DL
ion. Indeed
athogenesi
prognosis. W
e s t i g a c i
E d i t i o n
nction and
cology Grou
mark of an
Aberration
ose patien
uently, com
action is of
mphomage
elix transcr
hocytes, but
LBCL), whos
d, strong FO
s and clinic
We hypothe
ó n B i o m
2 0 1 4 ‐ 2
lymphomag
p / CIMA (L
ntibody‐me
ns in the GC
ts to imm
mprehensive
paramount
nesis. We h
ription facto
t that appe
se malignat
OXP1 expres
al behavior
size a pro‐o
é d i c a
0 1 5
genesis
Lab 1.08)
ediated imm
C reaction a
mune defici
e elucidatin
t importanc
have focuse
or that we
ears express
t transform
ssion appea
r of the activ
oncogenic
mune
nd its
ency,
g the
ce for
ed our
have
sed in
mation
ars to
vated
impa
and
stabi
lymp
omic
lymp
us t
epige
ident
dere
hum
corre
new
its ta
of DL
POSS
YES (
Our
inter
M á s t e
R e s
act of FOXP
BLIMP1 pat
ility of the G
phomagenic
c approach
phoma path
o identify
enetic insta
tified gene
gulation in
an DLBCL s
elation with
approache
argets' pro‐l
LBCL.
SIBILITY OF
(although fu
lab will co
rnational Ph
e r U n i v e
e a r c h P
P1 in coope
thways, by
GC B cell. W
c role and it
hes to ext
hogenesis do
important
ability, whic
etic and/o
our anima
amples and
h prognosis
s and nove
lymphomag
Ph.D. (YES/
unding cann
oordinate w
hD‐fellowsh
e r s i t a r i o
r o j e c t P
eration with
transcriptio
We propose
ts potential
end the u
ownstream
B cell FO
ch will be su
r epigenet
al studies, w
d cell lines,
and surviv
l therapeut
genic pressu
/NO)
not be imme
with the stu
ip opportun
o e n I n v e
r o p o s a l
h other DLB
onally dere
e to use sev
as a new t
understandi
FOXP1 acti
OXP1‐target
ubject of fu
tic biomar
will be the
exploring t
val. An ultim
ic strategie
ure, delayin
ediately wa
udent the
nities (e.g. F
e s t i g a c i
E d i t i o n
BCL‐recurre
gulating th
veral mouse
herapeutic
ing of GC
ivity. Our pr
ts that co
rther chara
rkers that
n analyzed
their value
mate goal o
s that could
ng or halting
arranted).
application
FPU, FPI, EU
ó n B i o m
2 0 1 4 ‐ 2
nt alteratio
e genomic
e models to
target. We
lymphocy
reliminary d
uld promo
acterization
are sensi
and valida
in clinical s
of this proje
d inactivate
g the malign
to potent
U actions …)
é d i c a
0 1 5
ons of the N
and epigen
o explore F
also plan t
yte biology
data has all
ote genetic
. Selected n
itive to F
ated in seri
stratification
ect is to pr
e FOXP1's an
nant progre
ial nationa
)
NF‐kB
nomic
OXP1
o use
y and
owed
c and
newly
OXP1
ies of
n and
ovide
nd/or
ession
l and
PROJ
Mech
DEPA
Labo
DIRE
Ignac
CONT
igbaz
SUM
Liver
durin
life. T
cells
prop
that
for N
meta
comp
(500,
after
after
M á s t e
R e s
JECT 26
hanisms of
ARTAMENT/
oratory 1.02
CTOR
cio Gil Bazo
TACT
MMARY
r metastase
ng the dise
The tumor
to migrate
posed as res
facilitates b
NSCLC liver
astasis from
pared; C57
,000) will b
r the injecti
r tumor cell
e r U n i v e
e a r c h P
liver metas
/LABORATO
2. Departme
o
s; 65674656
es appear in
ase course
microenviro
and spread
sponsible fo
breast canc
metastasis
m lung can
7BL/6 fema
be selected
on to avoid
s inoculatio
e r s i t a r i o
r o j e c t P
stasis in lung
ORY
ent of Onco
63.
n about 30%
with a dra
onment gen
d to the live
or this proc
cer cells to
s developm
ncer has b
ales vs. Id
for intrasp
d bulky flank
on. Weekly F
o e n I n v e
r o p o s a l
g cancer. Ro
logy, CIMA.
% of non‐sm
amatic impa
ne expressio
er. Howeve
cess. Id1 an
disseminat
ment. For th
been devel
d1‐knockout
plenic injec
k tumors fo
FDG‐micro‐
e s t i g a c i
E d i t i o n
ole of Id gen
.
mall cell lu
act on clinic
on might be
er, no candi
d Id3, mem
te to the lu
he first tim
oped. Two
t (KO). Le
ction. All m
ormation. M
‐positron em
ó n B i o m
2 0 1 4 ‐ 2
nes.
ng cancer (
cal outcom
e crucial for
date genes
mbers of the
ngs, might
e, a mouse
o cohorts o
ewis lung
ice will be
Mice will be
mission tom
é d i c a
0 1 5
(NSCLC) pat
e and qual
r allowing t
s have ever
e gene sign
be determ
e model of
of mice w
carcinoma
splenectom
closely foll
mography (P
tients
ity of
umor
been
ature
minant
f liver
ill be
cells
mized
owed
PET)
scans
Anim
lesio
analy
perfo
of ge
liver
POSS
YES
M á s t e
R e s
s will be pe
mals will be
ns will be o
ysis (Affym
ormed to ev
enes media
metastasis
SIBILITY OF
e r U n i v e
e a r c h P
erformed t
sacrificed a
obtained fo
etrix) with
valuate the
ating prolife
.
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
o study live
at the time
r RNA extra
the suppo
e potential i
eration, inva
/NO)
o e n I n v e
r o p o s a l
er metastas
of liver met
action (Qiag
ort of Ingen
impact of Id
asion, migr
e s t i g a c i
E d i t i o n
sis formatio
tastasis dev
gen kit). A m
nuity Pathw
d1 and Id3 g
ration, angi
ó n B i o m
2 0 1 4 ‐ 2
on in both
velopment.
microarray
ways Analys
genotype o
ogenesis an
é d i c a
0 1 5
groups of
Liver meta
gene expre
sis (IPA) w
on the regul
nd metasta
mice.
static
ession
will be
lation
asis in
PROJ
Prod
gastr
DEPA
Gene
DIRE
Rube
CONT
rube
Phon
SUM
The
base
aden
of ca
High
subst
thera
they
in viv
direc
M á s t e
R e s
JECT 27
uction and
rointestinal
ARTAMENT/
e Therapy a
CTOR
en Hernand
TACT
ne: 948 194
MMARY
project inv
d on ade
noviruses), a
ancer.
‐Capacity a
titution of t
apeutic gen
offer the o
vo and ach
cted gene th
e r U n i v e
e a r c h P
d applicatio
cancers
/LABORATO
nd Hepatol
ez Alcoceba
es
700 ext. 40
olves the d
novirus (H
and the cha
adenoviruse
the viral co
nes plus stu
pportunity
hieve susta
herapy appl
e r s i t a r i o
r o j e c t P
n of High‐C
ORY
ogy Unit, C
a
32
developmen
igh‐Capacit
aracterizatio
es (HC‐Ad)
ding seque
uffer DNA).
to deliver lo
ined gene
lications.
o e n I n v e
r o p o s a l
Capacity ad
IMA.
nt of long‐t
ty, also ca
on of their
) are a sp
nces with f
. Productio
ong fragme
expression
e s t i g a c i
E d i t i o n
denoviral ve
term gene t
alled helpe
function in
pecial class
foreign gene
n of these
ents of gene
. They are
ó n B i o m
2 0 1 4 ‐ 2
ectors in th
therapy exp
er‐dependen
vitro and in
s of vecto
es (expressi
vectors is
etic materia
especially
é d i c a
0 1 5
he treatme
pression ve
nt or “gut
n animal m
ors obtaine
ion cassette
challenging
al to an orga
suited for
ent of
ectors
tless”
odels
ed by
es for
g, but
anism
liver‐
Spec
Tech
POSS
Inter
if the
M á s t e
R e s
cific objectiv
Improve
Construc
(immuno
etc.)
Evaluatio
Evaluatio
o A
o A
li
niques:
Molecula
Cellular
Virology
Animal m
of gene t
SIBILITY OF
rnal funding
e candidate
e r U n i v e
e a r c h P
ves:
ement of me
ction of HC
ostimulator
on of the ve
on of the ve
Analysis of t
Analysis of a
iver cancer
ar biology (
biology
(virus rescu
models of d
therapy vec
Ph.D. (YES/
g for a Ph.D
or the proj
e r s i t a r i o
r o j e c t P
ethods for p
C‐Ads for e
ry cytokines
ectors in vit
ectors in viv
transgene e
antitumor e
subcloning,
ue, amplific
disease (est
ctors, evalu
/NO)
. program i
ect obtains
o e n I n v e
r o p o s a l
production
expression
s, molecules
tro (cell cult
vo:
expression
effect using
, plasmid co
cation, purif
tablishment
ation of ant
s not availa
s external fu
e s t i g a c i
E d i t i o n
of HC‐Ads.
of therape
s for modul
ture)
animal mo
onstruction)
fication and
t of tumors
titumor effe
able at this p
unding.
ó n B i o m
2 0 1 4 ‐ 2
eutic genes
lation of th
dels of pan
)
d titration)
s in rodents
ect and toxi
point. Ph.D
é d i c a
0 1 5
s against ca
e IGF‐I path
ncreatic, col
s, administr
icity)
. will be po
ancer
hway,
on or
ration
ssible
PROJ
Adva
negle
DEPA
Depa
Facu
DIRE
Mª S
CONT
sesp
SUM
Leish
leish
infec
cases
peop
beca
treat
avail
and p
M á s t e
R e s
JECT 28
anced ther
ected disea
ARTAMENT/
artment of
lty of Pharm
CTOR
Socorro Esp
TACT
uelas@una
MMARY
hmaniasis is
maniasis, C
ction (kala‐a
s a year, thr
ple currentl
use no effe
tment strat
able drugs
paromomyc
e r U n i v e
e a r c h P
apeutic str
se: nanotec
/LABORATO
Pharmacy a
macy, Unive
uelas Millán
v.es
s a zoonotic
CL) to ser
azar or VL)
reatens 350
ly infected
ective vacc
egies is con
(pentavale
cin, such as
e r s i t a r i o
r o j e c t P
rategies fo
chnology ap
ORY
and Pharma
ersity of Nav
n
c disease th
rious disfig
. WHO esti
0 million pe
worldwide
ine is avail
nsidered a p
ent antimon
toxicity, pr
o e n I n v e
r o p o s a l
or the trea
pproaches.
aceutical Te
varra
at ranges in
gurement (
imates that
eople in 88 c
. Current t
lable. The d
priority by
nials, desox
rice and/or
e s t i g a c i
E d i t i o n
atment of
echnology, I
n severity fr
(mucocutan
t the diseas
countries an
reatment is
developme
WHO in vie
xycholate a
long duratio
ó n B i o m
2 0 1 4 ‐ 2
leishmanio
Institute of
rom skin les
neous) and
se results i
nd that the
s based on
nt of oral a
ew of limita
mphoterici
on schedule
é d i c a
0 1 5
osis, a par
Tropical He
sions (cutan
d fatal syst
in 2 million
re are 12 m
n chemothe
and topical
ations of cu
n B, miltef
es of parent
rasitic
ealth,
neous
temic
n new
million
erapy,
l new
urrent
fosine
teral
admi
critic
The
phar
curre
prolo
admi
syste
lesio
beca
the t
resis
The
nano
prom
of VL
POSS
YES
M á s t e
R e s
inistrations
cal issue wo
aim of th
maceutical
ent chemot
ong over t
inistrations
ems and ph
ns. Immuno
use the im
treatments.
tance in the
developme
oparticles,
mastigotes a
L and CL.
SIBILITY OF
e r U n i v e
e a r c h P
. The emer
orldwide.
he project
formulatio
therapy. Bi
he time th
and the t
hotosensitiz
ostimulator
munologica
. Finally, na
e parasites.
ent of the p
the evalua
and infected
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
rgence of r
is to eval
n strategies
ioadhesive
he oral bio
toxic effect
ing agents
ry propertie
al state of t
notechnolo
projet inclu
ation of th
d macropha
/NO)
o e n I n v e
r o p o s a l
resistance t
luate the
s (nanopart
nanopartic
oavailability
ts. Metallic
in nanopar
es of these
the host pla
ogy approac
des the pr
heir activit
ages amast
e s t i g a c i
E d i t i o n
to common
performan
ticles) for ov
cles should
of drugs
c nanoparti
rticles prom
nanopartic
ay an impo
ches could o
eparation a
ty in vitro
igotes as w
ó n B i o m
2 0 1 4 ‐ 2
n drugs is a
ce of new
vercoming t
be able t
reducing th
cles, nitric
mise as local
cles can be
rtant role in
overcome t
and charact
against L
ell as in viv
é d i c a
0 1 5
also becom
w materials
the handica
to improve
he frecuen
oxide rele
l therapies
also very u
n the effica
the existing
terization o
Leishmania
vo in mice m
ming a
s and
aps of
e and
cy of
easing
of CL
useful
acy of
g drug
of the
spp.
model
PROJ
Adop
DEPA
Imm
CIMA
DIRE
Sand
CONT
mshe
SUM
Adop
spec
vacci
to giv
spec
their
deliv
imm
abilit
its ca
is als
M á s t e
R e s
JECT 29
ptive Cell Tr
ARTAMENT/
une Respon
A
CTOR
dra Hervás‐S
TACT
ervas@unav
MMARY
ptive T cell
ific T cells t
ination alon
ve their imm
ifically reco
r cognate A
very of biol
unotherape
ty to induce
apacity to su
so critical fo
e r U n i v e
e a r c h P
ransfer with
/LABORATO
nse Modula
Stubbs
v.es, 948‐19
therapy (A
to achieve
ne. The tum
mune syste
ognize antig
Ag. This p
ogical drug
eutic drug.
e and expan
uppress FO
or CD8 T cel
e r s i t a r i o
r o j e c t P
h genetically
ORY
ation labora
94700 (ext 4
ACT) involve
greater nu
mor specific
m the abilit
ens (Ag), T
roperty ma
gs. On the o
This cytok
nd cytotoxic
XP3 expres
l survival. H
o e n I n v e
r o p o s a l
y‐engineere
atory, Immu
4037)
es the isola
mber of T
c T cells are
ty to attack
cells are ret
akes them
other hand
kine exerts
c CD8 T cel
sion and th
However, sy
e s t i g a c i
E d i t i o n
ed T cells in
unology and
ation and e
cells than w
then infuse
k and kill can
tained in th
advantage
d, IL‐21 is n
potent an
ls, NK cells
e expansion
ystemic deliv
ó n B i o m
2 0 1 4 ‐ 2
cancer trea
d Immunoth
ex vivo expa
what could
ed into patie
ncer. Due t
ose tissues
eous vector
ow develo
titumor eff
and NKT ce
n of regulat
very of IL‐21
é d i c a
0 1 5
atment
herapy prog
ansion of t
be obtaine
ents with c
to their abil
s where they
rs for the
ped as a ca
ffects due t
ells, as well
tory T cells.
1 can cause
gram,
umor
ed by
ancer
lity to
y find
local
ancer
to its
as to
IL‐21
e
seve
is ne
cytok
to ex
by pr
expre
deve
objec
(2) I
activ
and (
this
sorti
mod
Imm
POSS
Only
M á s t e
R e s
re adverse
ecessary to
kine. We b
xpress IL‐21
rompting th
ession and
eloped a re
ctives of th
n vitro ch
vation, surv
(4) Measur
project: ret
ng, flow cy
els. Conce
unotherapy
SIBILITY OF
possible if
e r U n i v e
e a r c h P
effects. The
o develop n
elieve that
1 (ACT/IL‐21
heir expans
lessening
trovirus‐ba
his project a
haracterizat
ival), (3) In
e the antitu
trovirus pro
ytometry, ce
epts that
y of cancer.
Ph.D. (YES/
the Ph. D. s
e r s i t a r i o
r o j e c t P
erefore, in o
new strateg
the ACT dri
1) will maxi
ion and sur
the system
sed system
are: (1) Tra
ion of T c
vivo tracki
umor effica
opagation,
ell culture,
will be le
/NO)
student can
o e n I n v e
r o p o s a l
order to ex
gies that a
ven with tu
imize the a
rvival, and a
mic IL‐21‐a
m to allow t
nsduction o
cells expres
ing of gene
cy of ACT/I
cell transd
cell biology
earnt in t
n get a grant
e s t i g a c i
E d i t i o n
ploit the an
allow the lo
umor specif
antitumor e
also of IL‐21
ssociated t
the express
of T cells w
ssing IL‐21
etically‐mod
L‐21. Techn
uction, isol
y and basic
his projec
t
ó n B i o m
2 0 1 4 ‐ 2
ntitumor eff
ocal admin
ic cells gene
ffect of the
1, by allowin
toxicity. Re
sion of IL‐21
with retrovir
(effects o
ified IL‐21‐
niques that
lation of ce
c handling o
t: Immuno
é d i c a
0 1 5
ficacy of IL‐
istration of
etically‐mod
e infused T
ng its intrat
ecently we
1 in T cells
rus coding
on prolifera
‐expressing
will be lea
ells by mag
of animal t
o‐Oncology
‐21, it
f this
dified
cells,
umor
have
s. The
IL‐21,
ation,
cells,
rnt in
gnetic
umor
and
PROJ
Impli
steat
DEPA
Meta
DIRE
Direc
Co‐d
CONT
Direc
Co‐d
SUM
Non‐
steat
prese
obes
this a
M á s t e
R e s
JECT 30
ication of g
tohepatitis
ARTAMENT/
abolic Resea
CTOR
ctor: Amaia
irector: Gem
TACT
ctor: Amaia
e
P
irector: Gem
e
P
MMARY
‐alcoholic f
tohepatitis
entation an
sity, type 2
association
e r U n i v e
e a r c h P
ghrelin isof
associated
/LABORATO
arch Labora
Rodríguez
ma Frühbec
Rodríguez
e‐mail: arod
Phone numb
ma Frühbec
e‐mail: gfruh
Phone numb
fatty liver
(NASH),
nd evolutio
diabetes an
have not b
e r s i t a r i o
r o j e c t P
forms in th
to obesity a
ORY
atory, CUN.
Murueta‐G
ck Martínez
Murueta‐G
mur@unav
ber: 948 425
ck Martínez
hbeck@una
ber: 948 255
disease (NA
cirrhosis,
on. The pre
nd metabol
een fully elu
o e n I n v e
r o p o s a l
e onset of
and insulin
Goyena
z
Goyena
v.es
5 600 ext. 8
z
av.es
5 400 ext. 4
AFLD) inclu
and hepat
esence of N
lic syndrom
ucidated. In
e s t i g a c i
E d i t i o n
non‐alcoh
resistance
80 3357
4484
udes hepat
tocellular
NAFLD and
me, but the
n this sense
ó n B i o m
2 0 1 4 ‐ 2
olic fatty li
tic steatosi
carcinoma
NASH are
underlying
, ghrelin, a
é d i c a
0 1 5
iver disease
is, non‐alco
in its cl
associated
mechanism
hormone
e and
oholic
linical
with
ms for
invol
these
intra
induc
mod
POSS
YES.
M á s t e
R e s
lved in the
e patholog
peritoneal
ced by bar
el of diet‐in
SIBILITY OF
e r U n i v e
e a r c h P
control of f
gies. The a
administra
riatric surge
nduced obes
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
food intake
aim of the
tion of acy
ery on the
sity.
/NO)
o e n I n v e
r o p o s a l
and adipos
e present
ylated and d
control of
e s t i g a c i
E d i t i o n
sity, could c
study is
desacyl ghr
hepatic fu
ó n B i o m
2 0 1 4 ‐ 2
constitute t
to analyze
relin as wel
unction in a
é d i c a
0 1 5
the link bet
e the effe
ll as weigh
an experim
ween
ct of
t loss
mental
PROJ
Study
deve
DEPA
Meta
(Edif
DIRE
Direc
Co‐d
CONT
jagom
8065
SUM
The
nowa
cardi
a ma
More
deve
remo
tissu
M á s t e
R e s
JECT 31
y of the inv
elopment of
ARTAMENT/
abolic Rese
ficio CIFA)
CTOR
ctor: Javier
irector: Gem
TACT
mez@unav
567
MMARY
epidemic o
adays. Unh
iovascular d
ajor proces
eover, an
elopment of
odelling of
e could be t
e r U n i v e
e a r c h P
volvement
f obesity an
/LABORATO
earch Labo
Gómez Am
ma Frühbec
.es
of obesity
ealthy incre
disease and
ss in the e
alteration
f fibrosis. Th
the ECM w
the cause o
e r s i t a r i o
r o j e c t P
of extracel
d its comor
ORY
oratory, De
brosi
ck
poses one
eased adipo
cancer. Th
expansion
in the d
his project a
with a cons
of the como
o e n I n v e
r o p o s a l
lular matrix
rbidities
epartment
e of the m
ose tissue ra
e remodell
of adipose
deposition
addresses t
sequent inc
orbidities as
e s t i g a c i
E d i t i o n
x remodelli
of Endocri
most serious
aises the ris
ing of the e
e tissue th
of ECM p
he hypothe
crease in f
sociated wi
ó n B i o m
2 0 1 4 ‐ 2
ng in adipo
inology &
s public he
sk of type 2
extracellular
at takes p
proteins ca
esis that an
ibrotic dep
th obesity b
é d i c a
0 1 5
ose tissue i
Nutrition,
ealth challe
2 diabetes (
r matrix (EC
place in ob
an lead to
alteration i
posits in ad
by limiting
n the
CUN
enges
T2D),
CM) is
besity.
o the
in the
ipose
adipo
tissu
norm
fibro
will
analy
whet
dieta
anim
obes
deve
Meth
The f
Gene
Prote
M á s t e
R e s
ose tissue e
e of obese
moglycemic
osis with the
be studied
yzing their
ther circula
ary treatme
mal models
sity analysin
elopment an
hodology
following te
e expression
RNA
Nucle
Real
Analy
ein express
Prote
Prote
West
e r U n i v e
e a r c h P
expansion. T
e patients
lean subje
e expressio
. The pote
circulating
ating levels
ent (n=20)
how these
ng weight ga
nd gene exp
echniques w
n analysis
extraction f
eic acid qua
Time RT‐PC
ysis of gene
ion analysis
ein extractio
ein amount
tern blot &
e r s i t a r i o
r o j e c t P
The degree
with (n=2
cts (n=10)
n of ECM m
ential involv
concentrat
of these m
or bariatri
molecules
ain, energy
pression pro
will be used
from tissue
antitation a
CR.
e expression
s
on from tiss
quantitatio
zymograph
o e n I n v e
r o p o s a l
e of fibrosis
20) and wi
will be ana
molecules a
vement of
tions in a l
markers are
ic surgery
are involve
expenditur
ofile in epid
:
e.
nd quality a
n profiling b
sue.
on (Bradfor
hy.
e s t i g a c i
E d i t i o n
in visceral
thout T2D
alyzed. In a
as well as th
these prot
larger coho
e reversed
(n=20). In
ed in the de
re, adipose
idymal adip
assessment
by microarra
d).
ó n B i o m
2 0 1 4 ‐ 2
and subcut
(n=20) in
ddition, the
he comorbi
teins will b
ort (n=300)
after weigh
addition, w
evelopment
tissue and h
pose tissue
.
ays.
é d i c a
0 1 5
taneous ad
compariso
e relationsh
idities of ob
be corrobo
and elucid
ht loss follo
we will stu
t of diet‐ind
hepatic stea
and liver.
ipose
on to
hip of
besity
rated
dating
owing
dy in
duced
atosis
Imm
Proce
ELISA
Large
Hum
Anim
POSS
YES
M á s t e
R e s
unohystoch
essing of se
As.
e‐scale horm
man and rod
mal handling
SIBILITY OF
e r U n i v e
e a r c h P
hemical ana
erum and pl
mone analy
ent adipocy
g. Control o
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
alysis of pro
asma from
yses Multipl
yte culture.
f food intak
/NO)
o e n I n v e
r o p o s a l
oteins in hist
human and
ex (Lumine
ke, energy e
e s t i g a c i
E d i t i o n
tological pr
d rodents.
xTM 200).
expenditure
ó n B i o m
2 0 1 4 ‐ 2
eparations.
e and weigh
é d i c a
0 1 5
.
ht changes.
PROJ
Impa
gene
DEPA
Dpto
Phar
DIRE
Ame
CONT
Tel.+
SUM
The a
the d
cons
Obje
base
with
by a
para
Meth
subje
M á s t e
R e s
JECT 32
act of an in
etic and epig
ARTAMENT/
o. Ciencias
macy
CTOR
lia Marti de
TACT
+34 948 425
MMARY
aim of the p
developme
idering gen
ectives: 1 )
d on Medit
central obe
assessing ch
meters (gen
hodology:
ects from 7
e r U n i v e
e a r c h P
ntegral inte
genetic mar
/LABORATO
de la Alim
el Moral
5600 Ext. 80
project is to
nt of insul
etic and ep
To implem
terranean D
esity (7‐16
hanges in
netic and ep
Randomize
to 16 years
e r s i t a r i o
r o j e c t P
ervention in
rkers (IGEN
ORY
mentación y
06244; amar
o evaluate th
in resistanc
pigenetic ma
ent of a co
Diet (MD ) a
years) and
lifestyle fa
pigenetic m
d, controlle
s with centr
o e n I n v e
r o p o s a l
n Navarra
OI)
y Fisiología
he protectiv
ce (IR) in N
arkers.
omprehensi
nd increase
2 ) To mea
actors and
markers) .
ed, two‐ye
ral obesity, t
e s t i g a c i
E d i t i o n
children w
a, Facultad
s
ve effect of
Navarra chi
ive therape
ed physical
sure the ef
evaluating
ear interven
the effect o
ó n B i o m
2 0 1 4 ‐ 2
with diabete
de Farma
f an integral
ildren with
eutic interve
activity, in N
fectiveness
g biological
ntion in a
of two interv
é d i c a
0 1 5
es risk: stu
acia / Scho
l interventio
central ob
ention prog
Navarra chi
s of this pro
and mole
sample of
ventions: a
dy of
ool of
on on
besity
gram,
ildren
ogram
ecular
f 220
) an
inten
non‐
advic
asses
phys
inter
by g
gene
telom
and t
1
2
3
POSS
YES
M á s t e
R e s
nsive lifesty
intensive w
ce. At 3, 10,
ssed: a) H
ical activit
rvention gro
enotyping S
es related t
mere length
their parent
1. Moleres
2. Moleres
3. García‐C
SIBILITY OF
e r U n i v e
e a r c h P
yle based on
with health
, 17 and 24
OMA, body
y by appr
oup), c) qua
SNPs in RI
to RI; b) ex
h. The prog
ts.
s et al. FASE
s et al. Br J N
Calzón et al.
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
n DM, incre
hy diet re
months aft
y adiposity
ropriate qu
ality of life.
related ge
xpression o
gram will co
EB J. 2013; 2
Nutr. 2012;
. PLoS One.
/NO)
o e n I n v e
r o p o s a l
eased physi
ecommenda
ter the inte
y, and card
uestionnaire
Genetic and
nes, and th
of microRNA
onsist of th
27:2504‐12.
107:533‐8.
2014; 9(2):
e s t i g a c i
E d i t i o n
cal activity
ations follo
ervention th
diovascular
es and acc
d epigeneti
he analysis
As and targ
herapy sess
.
:e89828.
ó n B i o m
2 0 1 4 ‐ 2
and behav
owing stan
he following
risk factor
celeromete
c markers w
of: a) DNA
get genes r
sions aimed
é d i c a
0 1 5
vioural thera
ndard paed
g changes w
rs, b) diet,
er measure
will be evalu
A methylati
related to
d to partici
apy, )
diatric
will be
, and
ement
uated
on in
RI; c)
pants
PROJ
Obes
and m
DEPA
Func
Univ
DIRE
Direc
Co‐d
CONT
E‐ma
Phon
SUM
Diffe
incid
unde
obes
hypo
expre
this
analy
M á s t e
R e s
JECT 33
sity and can
methylation
ARTAMENT/
ctional Meta
ersidad de
CTOR
ctor: Victori
irector: Gem
TACT
ail: vcatalan
ne Number:
MMARY
erent epide
ence and m
erstood but
sity are sign
othesis tha
ession prof
project is t
ysing comm
e r U n i v e
e a r c h P
ncer: Study
n in colon ca
/LABORATO
abolomic La
Navarra.
ia Catalán
ma Frühbec
: 948 255 40
emiological
mortality of
t low‐grade
nificant fact
t obesity
file of key si
to study th
mon and par
e r s i t a r i o
r o j e c t P
of the invo
ancer deve
ORY
aboratory, D
ck
00 (x5133)
and clinica
f colon can
e inflamma
tors in the p
and the g
ignalling pa
he effect of
rallel gene e
o e n I n v e
r o p o s a l
olvement of
lopment in
Departmen
al studies
ncer. Under
ation, hypo
pathogenes
glycemic st
athways in c
f excess ad
expression c
e s t i g a c i
E d i t i o n
f adipose tis
obese patie
t of Endocr
show that
rlying mech
oxia and hy
sis of cance
tate under
colon cance
diposity in
changes in p
ó n B i o m
2 0 1 4 ‐ 2
ssue inflam
ents.
rinology & N
obesity is
anisms are
yperinsuline
r. This stud
rlay the ch
er developm
colon canc
pathways re
é d i c a
0 1 5
mmation, hy
Nutrition. C
s related to
e not comp
emia relate
dy addresse
hanges in
ment. The a
cer develop
elated to
ypoxia
Clínica
o the
letely
ed to
es the
gene
aim of
pment
inflam
from
blood
canc
subc
scale
and
inflam
prote
tumo
Meth
Samp
‐ S
‐ C
c
‐ R
‐ P
‐ B
‐ N
‐ P
‐ A
‐ A
‐ T
M á s t e
R e s
mmation, h
m obese pat
d samples
er. Patients
lassified ac
e gene expr
colon can
mmatory m
eins will be
our cells bet
hodology
ple process
Serum, plasm
Cellular isol
cells).
RNA isolatio
Protein extr
Biology mole
Nucleic acid
Protein quan
Analysis of g
Analysis of p
Tumour circ
e r U n i v e
e a r c h P
hypoxia or m
tients with
will be obt
s will be als
ccording to
ression ana
ncer will b
markers as
e determin
tween lean
ing:
ma and buf
lation from
on from adip
action from
ecular tech
quantitatio
ntitation an
gene expres
protein expr
ulating cells
e r s i t a r i o
r o j e c t P
methylation
and witho
tained from
so classified
the establ
alysis to dis
be studied
well as a
ed. Further
and obese
ffy coat extr
m adipose t
pose tissue
m adipose tis
niques:
on and qual
nd quality as
ssion by Rea
ression by W
s assessmen
o e n I n v e
r o p o s a l
n in viscera
out colon c
m a total of
d as lean or
lished diagn
sentangle s
. Circulatin
dipokines
rmore, diff
patients w
raction.
tissue (adi
and periph
ssue.
lity assessm
ssessment.
al‐time PCR
Western‐blo
nt by Real‐t
e s t i g a c i
E d i t i o n
al adipose t
cancer. Adip
f 60 patien
r obese. Ob
nostic thres
signalling pa
ng concent
and extrac
ferences in
ith colon ca
pocytes an
eral blood m
ment.
: TaqMan P
ot and zymo
time PCR.
ó n B i o m
2 0 1 4 ‐ 2
issue and p
pose tissue
nts with and
ese patient
sholds for
athways re
trations of
cellular mat
the numbe
ancer will be
nd stromov
mononuclea
Probes and T
ography.
é d i c a
0 1 5
peripheral b
e and perip
d without
ts will be fu
diabetes. L
lated to ob
f tumoural
trix remod
er of circu
e analysed.
vascular fra
ar cells.
TaqMan Ar
blood
pheral
colon
urther
Large‐
besity
and
elling
lating
action
rays.
Analy
‐ E
‐ L
‐ Im
POSS
YES
M á s t e
R e s
ytic techniq
ELISAs.
Large‐scale c
mmunohyst
SIBILITY OF
e r U n i v e
e a r c h P
ques:
cytokine an
tochemical
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
nalyses Mult
analysis of
/NO)
o e n I n v e
r o p o s a l
tiplex (Lum
proteins.
e s t i g a c i
E d i t i o n
inexTM 200)
ó n B i o m
2 0 1 4 ‐ 2
).
é d i c a
0 1 5
PROJ
Alzhe
DEPA
Neur
DIRE
Ana G
Mar
CONT
948 1
agos
mcua
SUM
The
mech
ident
of e
remi
used
disea
M á s t e
R e s
JECT 34
eimer Disea
ARTAMENT/
robiology of
CTOR
Garcia‐Osta
Cuadrado‐T
TACT
19 47 00 (20
adrado@un
MMARY
primary res
hanisms of
tify molecu
ffective ph
ssion of cli
d transgenic
ase from th
e r U n i v e
e a r c h P
ase: From M
/LABORATO
f Alzheimer
a
Tejedor
023)
s
nav.es
search in ou
cognitive d
lar neurobi
harmacolog
nical manif
c mouse m
e molecular
e r s i t a r i o
r o j e c t P
Molecular Bi
ORY
r´s disease.
ur lab is de
eficits, spec
ological ab
ical treatm
festations a
models of A
r to the beh
o e n I n v e
r o p o s a l
iology to Th
Neuroscien
evoted to th
cifically in A
normalities
ments to sl
associated w
AD, where
havioural po
e s t i g a c i
E d i t i o n
herapy
nce at CIMA
he discover
Alzheimer's
s which cou
ow or halt
with the dis
we can stu
oint of view
ó n B i o m
2 0 1 4 ‐ 2
ry of cellula
disease (AD
ld help in t
t disease p
sease. Towa
udy the ma
w. We also u
é d i c a
0 1 5
ar and mole
D). Our goa
he develop
progression
ard this go
ain signs o
use these m
ecular
l is to
pment
n and
al we
of the
mouse
mod
treat
More
such
new
syna
of dr
induc
mem
POSS
M á s t e
R e s
els to test
tments.
e specifical
as histone
therapeut
ptic plastici
rugs (histon
ction of ne
mory phenom
SIBILITY OF
e r U n i v e
e a r c h P
t pre‐clinic
lly we are
acetylation
ic targets.
ity processe
e deacetyla
urotoxicity
mena.
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
cally the p
interested
n, alter gene
We study
es that occu
ase inhibito
processes
/NO) Yes
o e n I n v e
r o p o s a l
potential th
in underst
e expressio
the molec
ur in situat
rs, phospho
and, in par
e s t i g a c i
E d i t i o n
herapeutic
tanding ho
n, which co
cular chang
ions such a
odiesterase
rticular, tho
ó n B i o m
2 0 1 4 ‐ 2
relevance
w epigenet
ould lead to
ges associat
s continued
inhibitors,
ose related
é d i c a
0 1 5
of novel
tic mechan
identificati
ted to ada
d administr
growth fac
to learning
drug
nisms,
ion of
aptive
ration
ctors),
g and
PROJ
Asse
DEPA
Neur
DIRE
Marí
CONT
mfse
SUM
ASL p
(CBF
of AS
appli
perfu
used
perfu
infor
disea
asses
proje
M á s t e
R e s
JECT 35
ssment of r
ARTAMENT/
roimagen La
CTOR
ía Asunción
TACT
eara@unav.
MMARY
perfusion M
) and functi
SL to provi
ications. In
usion abnor
d to guide
usion and
rmation. In
ase patient
ssment of f
ect will invo
e r U n i v e
e a r c h P
resting state
/LABORATO
aboratory, N
Fernández
.es, 948‐194
MRI offers t
ional conne
ide absolut
studies co
rmalities in
the funct
functiona
previous w
s. The goa
functional
olved proces
e r s i t a r i o
r o j e c t P
e brain func
ORY
Neuroscien
Seara
4700, ext. 2
he unique p
ectivity (1) u
te quantific
omparing p
the disease
tional conn
l connecti
work (1), we
l of this pr
connectivity
ssing of neu
o e n I n v e
r o p o s a l
ctional conn
ce, CIMA
2035
possibility o
using data a
cation of b
patients to
ed brain wi
nectivity an
ivity abno
e have evalu
roject is to
y abnorma
uroimaging
e s t i g a c i
E d i t i o n
nectivity in
of measurin
acquired in a
aseline CBF
controls, t
ll yield cruc
nalysis. Sim
rmalities w
uated perfu
o explore t
lities in the
data, using
ó n B i o m
2 0 1 4 ‐ 2
Parkinson's
ng both cere
a single sca
F is very us
he assessm
cial informa
multaneous
will yield
usion deficit
he use of A
e same pat
existing to
é d i c a
0 1 5
s disease
ebral blood
n. The capa
seful for cl
ment of bas
ation that ca
assessme
compleme
ts in Parkin
ASL data in
tient group
ols.
d flow
ability
linical
seline
an be
nt of
entary
nson's
n the
p. The
Refe
(1) R
appli
(2) F
using
2011
POSS
YES
M á s t e
R e s
rences:
Rosazza C,
ications. Ne
ernández‐S
g arterial sp
1 Oct 18.
SIBILITY OF
e r U n i v e
e a r c h P
et al. Res
eurol Sci. 20
Seara MA, e
pin labeled p
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
sting‐state
011 Oct;32(5
et al. Cortic
perfusion M
/NO)
o e n I n v e
r o p o s a l
brain netw
5):773‐85. E
cal hypoper
MRI. Neuroim
e s t i g a c i
E d i t i o n
works: lite
Epub 2011 J
fusion in Pa
mage. 2012
ó n B i o m
2 0 1 4 ‐ 2
rature revi
Jun 11. Rev
arkinson's d
2 Feb 1;59(3
é d i c a
0 1 5
iew and cl
view.
disease asse
3):2743‐50.
linical
essed
Epub
PROJ
Healt
form
DEPA
Depa
DIRE
Two
CONT
dans
SUM
Oxys
gene
requ
cause
they
Chole
inflam
athe
(oxyp
M á s t e
R e s
JECT 36
th implicat
mation
ARTAMENT/
artamento d
CTOR
co‐director
TACT
sorena@una
MMARY
sterols (SO
erated in t
iring enzym
ed by heat
could be ab
esterol oxid
mmatory e
rosclerotic
phytosterol
e r U n i v e
e a r c h P
tions of st
/LABORATO
de Ciencias
rs: Iciar Asti
av.es (Ext 8
Ps: oxidize
the human
mes. Oxyste
ting treatm
bsorbed fro
dation prod
ffects and
and neur
s) have also
e r s i t a r i o
r o j e c t P
terols´ oxid
ORY
de la Alime
asarán and
06263)
ed derivati
n organism
rols are also
ents, conta
om the diet.
ducts (COP
they have
rodegenerat
o been linke
o e n I n v e
r o p o s a l
dation prod
entación y F
Diana Anso
ves of ch
through
o present in
act with ox
.
Ps) have sh
also been l
tive proce
ed to toxic e
e s t i g a c i
E d i t i o n
ducts and
Fisiología
orena
olesterol a
different o
n food due
xygen, expo
own cytoto
linked with
sses. Oxys
effects, alth
ó n B i o m
2 0 1 4 ‐ 2
factors in
and phytos
oxidation p
to lipid oxi
osure to su
oxicity, apo
chronic di
terols from
hough at hig
é d i c a
0 1 5
nvolved in
sterols) ca
processes,
dation reac
nlight, etc.
optotic and
seases incl
m plant st
gher doses.
their
n be
some
ctions
, and
pro‐
uding
terols
The
form
pote
Dete
spect
this
num
Ot
Ox
20
M
As
fa
An
M
m
POSS
Yes
M á s t e
R e s
project wil
mation of S
ntial applic
ermination o
trometry a
equipment
ber of comp
taegui‐Arra
xysterols: a
010
Menéndez‐C
stiasarán, I
actors. Nutr
nsorena, D.
M.T. Thermo
matrix. Food
SIBILITY OF
e r U n i v e
e a r c h P
ll evaluate
SOPs under
ation on bio
of the SOP
nalysis. Wid
t is offered
pounds.
azola, A.,
a world to e
arreño, M
. Correlatio
ición Hospit
., Barriuso,
o‐oxidation
Chemistry
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
the interac
r several c
ological sam
s content w
de experien
d, that can
Menéndez
explore. Fo
., Varo, N
on between
talaria 26(1
B., Cardeni
of choleste
141, 2757‐2
/NO)
o e n I n v e
r o p o s a l
ction betw
conditions.
mples will be
will be carr
nce in acqu
be further
z‐Carreño,
ood and Che
N., Muguet
n serum C
1), 144
a, V. Astias
erol: effect o
2764. 2013
e s t i g a c i
E d i t i o n
een sterols
Model sys
e also inclu
ried out by
uiring skills
r applied f
M., Anso
emical Toxi
ta, C., Res
OPs from
‐151. 201
arán, I., Ler
of the unsa
ó n B i o m
2 0 1 4 ‐ 2
s and antio
tems will
ded.
gas chrom
in the use
or the ana
orena, D.,
icology, 48(
stituto, P.,
autoxidatio
11
rcker G., Ro
turation de
é d i c a
0 1 5
oxidants on
be applied
matography‐
and handli
alysis of a
Astiasará
(12), 3289‐
, Ansorena
on and CVD
odriguez‐Est
egree of the
final
d and
‐mass
ng of
great
n, I.
3303.
a, D.,
D risk
trada,
e lipid
PROJ
Deve
DEPA
Depa
DIRE
Carlo
Ana
CONT
cgam
SUM
Ente
diarr
to th
studi
again
effec
ende
be af
In th
of ac
M á s t e
R e s
JECT 37
elopment of
ARTAMENT/
artment of M
CTOR
os Gamazo
I. Camacho
TACT
mazo@unav
MMARY
rotoxigenic
rhea in youn
hese areas.
ied, and di
nst these b
ctive in the
emic areas.
ffordable fo
is context, o
celullar vacc
e r U n i v e
e a r c h P
f a subcellu
/LABORATO
Microbiolog
v.es, Tel: 948
c Escherichia
ng children
Pathogene
ifferent str
bacteria. Ho
most impo
Besides, th
or use in poo
our approa
cines. Never
e r s i t a r i o
r o j e c t P
lar vaccine
ORY
gy, Universi
8 425688
a coli (ETEC
living in en
esis and im
ategies hav
owever, no
rtant target
his vaccine h
or countrie
ch is based
rtheless, saf
o e n I n v e
r o p o s a l
against Ent
ity of Navar
C) strains ar
demic coun
mune resp
ve been ta
ETEC cand
t groups, w
has to be b
s where it i
on the safe
fety of this
e s t i g a c i
E d i t i o n
terotoxigen
rra
e the most
ntries and c
onse referr
aken to dev
didate vacc
which are inf
oth practica
s needed.
est available
kind of sub
ó n B i o m
2 0 1 4 ‐ 2
ic Escherich
common b
hildren and
ring to ETEC
velop an e
ine has bee
fants and y
al and inexp
e strategy: t
cellular vac
é d i c a
0 1 5
hia coli (ETE
acterial cau
d adults trav
C has been
effective va
en shown t
young childr
pensive so
the employ
ccines is usu
EC)
use of
veling
n well
accine
to be
ren in
it can
yment
ually
ham
adeq
admi
Thus
Prep
up
inmu
POSS
M á s t e
R e s
pered with
quate immu
inistration w
s, the parti
aration of s
protocol;
unogenicity
SIBILITY OF
e r U n i v e
e a r c h P
a lower inh
une respons
will be used
al objetive
subcellular
(ii) Charac
of OMV ex
Ph.D. (YES)
e r s i t a r i o
r o j e c t P
herent imm
se and thin
d.
s for final
extracts fro
cterization
tract in mo
o e n I n v e
r o p o s a l
munogenicit
nking about
consecutio
om E. coli u
to proteo
use models
e s t i g a c i
E d i t i o n
y. Consequ
t the epide
on of the
using a repr
omic level
s.
ó n B i o m
2 0 1 4 ‐ 2
ently, in or
miology of
proyect are
roducible m
; (iii) Eva
é d i c a
0 1 5
rder to obta
E. coli, mu
e as follow
method for s
aluation of
ain an
ucosal
ws: (i)
scale‐
f the
PROJ
Regu
DEPA
Depa
Phar
Scien
DIRE
Dr. F
CONT
F. Mi
C. de
SUM
Cave
with
regu
and h
micro
this p
gene
mou
DNA
M á s t e
R e s
JECT 38
ulation of Ca
ARTAMENT/
artment of N
macy and D
nce
CTOR
ermín Mila
TACT
ilagro: fmila
e Miguel: cd
MMARY
eolin‐1 has b
the regulat
lation of Ca
has found t
oRNAs have
project the
e expression
se Caveolin
into report
e r U n i v e
e a r c h P
aveolin‐1 ex
/LABORATO
Nutrition Fo
Department
gro Yoldi an
agro@unav
dmiguel@un
been shown
tion of insul
aveolin‐1 ge
hat epigene
e been also
aim will be
n by microR
n‐1 gene wil
ter vectors c
e r s i t a r i o
r o j e c t P
xpression by
ORY
ood Science
t of Biochem
nd Dr. Carlo
.es Phone:8
nav.es Phon
n to have a
lin sensitivit
ene express
etic mechan
pointed as
to study th
RNAs. For th
l be cloned
carrying the
o e n I n v e
r o p o s a l
y microRNA
e and Physio
mistry and G
os de Migue
806553
ne:806462
key role in o
ty. Our grou
ion in the p
nisms are im
key regulat
he regulatio
his purpose
by PCR am
e luciferase
e s t i g a c i
E d i t i o n
As
ology, Schoo
Genetics, Sc
el Vázquez.
obesity in c
up has stud
process of ad
mportant (1
tors in such
n of the Cav
the 3’ regio
plification o
gene. This
ó n B i o m
2 0 1 4 ‐ 2
ol of
chool of
onnection
ied the
dipogenesis
). Since
process, in
veolin‐1
on of the
of genomic
constructio
é d i c a
0 1 5
s
n
on
will b
prea
the a
teste
have
or hi
such
1. Ex
adipo
Vare
One.
POSS
YES (
M á s t e
R e s
be assayed f
dypocites. D
adipogeneti
ed (mir103 a
e influence i
gh glucose
conditions
xpression of
ocyte differ
la‐Gurucea
2014. 9(4)
SIBILITY OF
(Depending
e r U n i v e
e a r c h P
for microRN
Different m
ic process, a
and mir107
n the proce
levels, will
.
f Caveolin 1
rentiation. S
ga, M., Mila
:e95100. do
Ph.D. (YES/
g on funding
e r s i t a r i o
r o j e c t P
NA regulatio
microRNAs a
as well as of
). The effec
ess, such as
be also stud
is enhance
Status of ins
agro, F.I., M
oi: 10.1371
/NO)
g and perfor
o e n I n v e
r o p o s a l
on of expre
lready repo
f Caveolin‐1
ct of severa
inflammati
died by incu
ed by DNA d
sulin signall
Martínez, J.A
rmance of t
e s t i g a c i
E d i t i o n
ssion in 3T3
orted as reg
1 expression
l factors kno
ion (TNF‐�),
ubating the
demethylati
ing. Palacio
A. and, de M
the candida
ó n B i o m
2 0 1 4 ‐ 2
3‐L1
ulators of
n, will be
own to
, hypoxia,
cells in
on during
os‐Ortega, S
Miguel, C. PL
te)
é d i c a
0 1 5
S.,
LoS
PROJ
Regu
resis
DEPA
Depa
Scho
DIRE
Marí
CONT
mjm
SUM
Obes
inflam
disor
meta
pote
acids
these
inflam
The
prore
M á s t e
R e s
JECT 39
ulation of
tance: effec
ARTAMENT/
artment of
ool of Pharm
CTOR
ía Jesús Mo
TACT
oreno@una
MMARY
sity is a se
mmation as
rders linked
abolic synd
ntial benef
s of marine
e beneficia
mmation in
project wi
esolving lip
e r U n i v e
e a r c h P
adipose t
cts of specia
/LABORATO
Nutrition,
macy
reno Aliaga
av.es/ ext. 8
erious and
ssociated w
d to obesit
rome. Seve
ficial effect
origin (EPA
al actions o
n adipose tis
ill focus in
id mediator
e r s i t a r i o
r o j e c t P
issue meta
alized prore
ORY
Food Scien
a.
806558
growing
with obesity
ty, such as
eral studies
ts of consu
A and DHA)
of omega‐3
ssue and to
n studying
rs (resolvins
o e n I n v e
r o p o s a l
abolism in
esolving lipi
ces and Ph
public hea
contribute
s insulin re
s and clinic
umption /
) in these p
3 may in p
modulate
the poten
s and mares
e s t i g a c i
E d i t i o n
obesity,
d mediator
hysiology /
lth problem
s to the dev
sistance, ca
cal investig
supplemen
pathologies.
part result
its metabol
tial benefi
sins), endog
ó n B i o m
2 0 1 4 ‐ 2
inflammati
s.
Nutrition R
m. The low
velopment o
ardiovascul
ations have
tation with
It has bee
from its a
ism and sec
cial actions
genous lipid
é d i c a
0 1 5
ion and in
Research Ce
w‐grade ch
of the meta
ar diseases
e suggested
h omega‐3
n proposed
bility to re
cretory func
s of specia
d derivative
nsulin
enter.
hronic
abolic
s and
d the
fatty
d that
educe
ction.
alized
s of
omeg
mole
on th
and
secre
gluco
POSS
YES
M á s t e
R e s
ga‐3, in
ecular mech
he study of
the factor
etion of so
ose and lipid
SIBILITY OF
e r U n i v e
e a r c h P
obesity an
hanisms inv
f: 1) their ac
rs that pro
ome adipok
d metabolis
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
nd associat
olved will b
ctions on th
omote brow
kines with
sm.
/NO)
o e n I n v e
r o p o s a l
ted metabo
be studied i
he regulatio
wn phenoty
a key role
e s t i g a c i
E d i t i o n
olic compl
n cultured a
on of lipoge
ype in wh
e in regulat
ó n B i o m
2 0 1 4 ‐ 2
ications. Th
adipocytes,
enesis, lipol
ite adipose
ting insulin
é d i c a
0 1 5
he cellular
, mainly foc
lysis, autop
e tissue; 2
n sensitivity
r and
cusing
hagy,
) the
y and
Diffe
deac
DEPA
Phar
DIRE
Dr. R
Dr. E
CONT
rtord
SUM
Rece
inhib
chall
desig
More
find c
Vorin
class
M á s t e
R e s
PROJECT 40
erential reg
cetylase inh
ARTAMENT/
macology a
CTOR
Rosa M. Tor
Elena Puerta
TACT
dera@unav
MMARY
ent discove
bitors for
enge now
gn highly
eover, the s
compounds
nostat (sub
s I and II HD
e r U n i v e
e a r c h P
gulation of
ibitors
/LABORATO
and Toxicolo
dera Bavier
a Ruiz de Az
.es
eries have
their effec
would be t
selective c
study of th
s able to cro
eroylanilide
AC inhibito
e r s i t a r i o
r o j e c t P
f synaptic
ORY
ogy (School
ra
zúa
awakened
cts on neu
to find the
compounds
ese drugs i
oss the bloo
e hydroxam
rs. In the CN
o e n I n v e
r o p o s a l
plasticity
of Pharmac
d the inter
urodegener
e specific H
s that cou
involves the
od‐brain ba
mic acid/ SA
NS, vorinost
e s t i g a c i
E d i t i o n
markers a
cy, Universi
rest of his
rative and
HDAC enzym
uld cause
e additiona
rrier.
AHA) and g
tat has show
ó n B i o m
2 0 1 4 ‐ 2
nd behavio
ity of Navar
stone deac
psychiatric
mes of inte
only the
l complicat
givinostat a
wn antidep
é d i c a
0 1 5
our by his
rra)
cetylase (H
c diseases.
erest in ord
desired ef
tion of havi
re non‐sele
ressant and
stone
HDAC)
The
der to
ffects.
ng to
ective
d
neur
inflam
class
mod
MC1
study
mark
class
POSS
Yes
M á s t e
R e s
roprotective
mmatory p
s III (sirtuin
els. Other
568 and th
y the effec
kers and be
s I, II and III
SIBILITY OF
e r U n i v e
e a r c h P
e action in
properties a
ns) HDAC i
more selec
e Sirt2 inhi
ct of these
ehaviour. W
HDACs as ta
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
animal mo
and has also
inhibitor sh
ctive HDAC
bitor 33i ha
five comp
We would l
argets for n
/NO)
o e n I n v e
r o p o s a l
odels. Givin
o neuropro
howing ben
C inhibitors
ave not yet
ounds in h
like to expl
neurological
e s t i g a c i
E d i t i o n
ostat, is ve
otective act
neficial effe
s such as t
t been stud
histone ace
ore in dept
l and psych
ó n B i o m
2 0 1 4 ‐ 2
ery well‐kno
tivity. Simila
ects in neu
he class II
ied in the b
tylation, sy
th the pote
iatric disord
é d i c a
0 1 5
own for its
arly, sirtino
urodegener
HDAC inh
brain. We a
ynaptic plas
ential intere
ders.
anti‐
ol is a
rative
ibitor
im to
sticity
est of
PROJ
Valid
DEPA
Depa
Nutr
DIRE
Ferm
CONT
fmila
jalfm
SUM
Epige
main
used
our c
follow
treat
respo
the d
M á s t e
R e s
JECT 41
dation of ep
ARTAMENT/
artment of N
ition Resea
CTOR
mín Milagro;
TACT
agro@unav.
MMARY
enetic proc
n goal in th
d as biomar
case, a met
wed a die
tment have
onders to t
diet).
e r U n i v e
e a r c h P
pigenetic bio
/LABORATO
Nutrition, F
rch Center.
; J. Alfredo
.es. Teléfon
es; 9484256
esses are im
his field has
rkers of ear
hylation mi
tary interv
been comp
he treatme
e r s i t a r i o
r o j e c t P
omarkers in
ORY
ood Science
University
Martínez.
no 94842560
00 ext. 806
mportant re
s been the
rly predictio
icroarray ha
vention to
pared, but
ent (in orde
o e n I n v e
r o p o s a l
n blood cells
e and Physi
of Navarra.
00 ext 8065
6424.
egulators o
identificati
on of diseas
as been per
lose weigh
also the ba
er to identif
e s t i g a c i
E d i t i o n
s in relation
ology.
.
553.
of gene exp
on of epige
se or to pe
rformed in
ht. The val
aseline value
fy markers s
ó n B i o m
2 0 1 4 ‐ 2
n to obesity
ression. In
enetic mark
rsonalize th
obese volun
ues before
es of the go
specific for
é d i c a
0 1 5
and the die
the last ye
ks that cou
he treatme
nteers that
e and afte
ood and the
the respon
et
ars, a
uld be
nt. In
have
r the
e bad
nse to
The
(pyro
THP‐
Some
alone
or co
Refe
‐ Epi
obes
Bioch
‐ Die
persp
‐ Diff
loss
al.FA
POSS
YES
M á s t e
R e s
current pro
osequencing
‐1) before a
e of these
e or in the
onditioned m
rences:
genetic pat
sity conditio
hemistry (In
etary facto
pectives.Mi
ferential DN
interventio
ASEB Journa
SIBILITY OF
e r U n i v e
e a r c h P
oject involv
g, HRM) in
nd after the
biomarkers
process of
medium.
tterns of tw
on and diet
n Press)
ors, epigen
ilagro FI et a
NA methyla
n in overwe
al 2013; 27:
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
ves the vali
both, bloo
e differentia
s will also
differentiat
wo gene pr
tary intake
etic modif
al.Molecula
tion patter
eight/obese
2504‐2512
/NO)
o e n I n v e
r o p o s a l
idation of t
od cells and
ation to ma
be tested i
tion in the
romoters (T
.Gómez‐Uri
fications an
ar Aspects o
ns between
e adolescen
.
e s t i g a c i
E d i t i o n
the epigene
d cultured h
acrophages.
in human a
presence o
TNF‐α and
iz AM et al
nd obesity
of Medicine
n high and l
nts: The EVA
ó n B i o m
2 0 1 4 ‐ 2
etic marks
human mon
adipocytes
f macropha
PON) in str
l.Journal of
outcomes
2013; 34: 7
low respond
ASYON stud
é d i c a
0 1 5
by other m
nocytes (ce
in culture,
ages (co‐cu
roke consid
f Physiology
s: progress
782‐812.
ders to a w
dy. Moleres
means
ll line
both
lture)
dering
y and
s and
weight
s A et
PROJ
Oxid
study
DEPA
Depa
Nutr
DIRE
M. Á
CONT
Tel.+
Tel.+
SUM
Strok
2nd c
habit
disea
throu
healt
healt
by re
show
lowe
M á s t e
R e s
JECT 42
ative stress
y
ARTAMENT/
artment of N
ition Resea
CTOR
Ángeles Zule
TACT
+34 948 425
+34 948 425
MMARY
ke remains
cause of mo
ts, have be
ases such as
ugh simple
thy diet, an
thy lifestyle
eduction of
wn that sub
er C‐reactive
e r U n i v e
e a r c h P
s and infla
/LABORATO
Nutrition, F
rch Center.
et / Itziar Ab
5600 Ext. 80
5600 Ext. 80
one of the
ortality afte
een recogn
s stroke. Ac
e and modi
nd regular
e in the car
f inflammat
bjects with
e protein (P
e r s i t a r i o
r o j e c t P
mmatory b
ORY
ood Science
University
bete
06424; jalfm
06357; itziar
most deva
er ischemic
nized as im
ccordingly, t
ifiable prev
activity. Th
diovascular
tion and ox
higher adh
PCR) plasma
o e n I n v e
r o p o s a l
biomarkers
e and Physi
of Navarra.
r.imperial@
astating neu
heart disea
mportant d
this pandem
ventive me
he benefici
r risk reduc
xidative stre
erence to a
a levels and
e s t i g a c i
E d i t i o n
in the risk
ology.
.
es
@gmail.com
urological d
ase. Lifestyl
eterminant
mic could b
asures suc
ial effects
tion are hy
ess concent
a Mediterra
lower oxidi
ó n B i o m
2 0 1 4 ‐ 2
k of stroke
diseases and
e factors, e
ts of major
be in great p
h as smok
of a health
pothesized
tration. Ma
anean dieta
ized low de
é d i c a
0 1 5
: a case‐co
d represent
especially di
r cardiovas
part preven
king cessati
hy eating a
to be med
ny authors
ary pattern
nsity lipopr
ontrol
ts the
ietary
scular
ntable
on, a
and a
diated
have
have
rotein
conc
vege
cons
stres
Thus
inflam
mon
like L
Meth
Two
study
circu
and d
Refe
‐
preve
‐
antio
large
‐
Scarm
infar
2011
POSS
M á s t e
R e s
centration (
etables and
umption of
ss biomarke
s, the obje
mmatory c
ocyte chem
LDL‐ox in as
hods
hundred s
y. Variables
umference),
diet throug
rences
Awan Z
ention. Eur
Del Rio
oxidant cap
e Italian coh
Gardene
meas N. M
rction, and
1;94:1458‐6
SIBILITY OF
e r U n i v e
e a r c h P
LDL‐ox). Lik
d fruits, le
f red wine
ers, decreas
ective of t
cytokines su
moattractan
ssociation w
ubjects (10
s obtained
lifestyle ha
h a food fre
Z, Genest
J Prev Card
D, Agnoli C
pacity of the
hort. J Nutr.
er H, Wright
Mediterrane
vascular d
64.
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
kewise, whe
gumes, wh
are negativ
ing the risk
the study
uch as PCR
nt protein‐1
with lifestyle
00 controls/
were: anth
abits (alcoh
equency que
J. Inflamm
diol. 2014 (in
C, Pellegrin
e diet is as
2011;141:1
t CB, Gu Y, D
ean‐style d
death: the
/NO) NO
o e n I n v e
r o p o s a l
en foods are
hole cerea
vely associa
of stroke in
is to anal
R, tumor n
1 (MCP‐1) a
e variables o
/100 patien
hropometric
hol consum
estionnaire
mation mod
n press).
i N, Krogh
ssociated w
118‐23.
Demmer RT
diet and r
Northern
e s t i g a c i
E d i t i o n
e separately
ls, olive o
ated with i
ncidence.
lyze plasm
necrosis fac
and some o
on the risk o
nts with str
c measures
ption, smo
e) and blood
dulation an
V, Brighen
with lower r
T, Boden‐Alb
risk of isc
Manhatta
ó n B i o m
2 0 1 4 ‐ 2
y analyzed,
oil, nuts, fi
nflammator
a concentr
ctor‐α (TNF
oxidative st
of suffering
roke) were
s (weight, h
king habit,
d samples.
nd cardiov
ti F, Mazze
risk of ische
bala B, Elkin
hemic stro
n Study. A
é d i c a
0 1 5
consumpti
ish, and a
ry and oxid
ration of
F‐α), chem
tress bioma
g a stroke.
enrolled i
height and
physical ac
vascular di
eo T et al.
emic stroke
nd MS, Sacc
oke, myoca
Am J Clin
on of
a low
dative
some
okine
arkers
n the
waist
ctivity
sease
Total
e in a
co RL,
ardial
Nutr.
PROJ
Epige
restr
DEPA
Depa
Nutr
DIRE
M. Á
CONT
Tel.+
Tel.+
SUM
Intro
nono
mark
also
sense
the e
meta
M á s t e
R e s
JECT 43
enetic mod
riction: RESM
ARTAMENT/
artment of N
ition Resea
CTOR
Ángeles Zule
TACT
+34 948 425
+34 948 425
MMARY
oduction: O
obese indiv
ks could be
associated
e, more stu
epigenetic
abolic syndr
e r U n i v e
e a r c h P
difications i
MENA proje
/LABORATO
Nutrition, F
rch Center.
et / J. Alfred
5600 Ext. 80
5600 Ext. 80
Obese peop
iduals. The
used as ea
with the s
udies are ne
markers an
rome.
e r s i t a r i o
r o j e c t P
n obese pa
ect
ORY
ood Science
University
do Martínez
06317; mazu
06424; jalfm
ple have a
identificat
rly predicto
susceptibilit
eeded to ev
nd the pos
o e n I n v e
r o p o s a l
atients wit
e and Physi
of Navarra.
z
ulet@unav.
a pattern
tion and un
ors of meta
ty or resist
valuate the
ssibility of
e s t i g a c i
E d i t i o n
h metaboli
ology.
.
.es
es
of epigene
nderstandin
bolic risk. E
tance to we
effect of w
reverse the
ó n B i o m
2 0 1 4 ‐ 2
ic syndrom
etic marks
g of the ro
Epigenetic m
eight loss a
weight loss i
em in obes
é d i c a
0 1 5
me under e
different
ole of epige
marks have
and gain. In
interventio
se patients
nergy
from
enetic
been
n this
ns on
with
Obje
meth
bioch
Meth
(Met
focus
(Ame
mont
bioch
were
comp
as th
supp
1
2
3
POSS
YES
M á s t e
R e s
ective: The
hylation lev
hemical bio
hodology:
tabolic synd
sed on imp
erican Hear
ths. The n
hemical ma
e analyzed
plete the D
he statistic
ported by pr
1. de la Igle
2. López‐Le
3. Milagro
SIBILITY OF
e r U n i v e
e a r c h P
aim of th
vels of gene
omarkers at
This inves
drome Red
proving me
rt Associat
utritional i
arkers (lipid/
before and
NA isolatio
analysis of
revious artic
esia R et al.
egarrea. J C
FI et al. FAS
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
is work is
es related t
baseline an
stigation c
uction in N
etabolic syn
ion vs RES
ntervention
/glucose pr
d after the
n from whit
the results
cles of this
Br. J. Nutr.
lin Biochem
SEB J. 2011;
/NO)
o e n I n v e
r o p o s a l
to assess
to metabol
nd after six
considers a
Navarra) wh
ndrome fea
SMENA diet
n has been
rofile, inflam
dietary imp
te blood ce
s to reach
investigatio
2014; 111(
m Nutr. 2013
;25(4):1378
e s t i g a c i
E d i t i o n
the poten
lic syndrom
months und
a subsamp
hich is a ra
atures throu
t) designed
n concluded
mmatory an
plementatio
ells and DNA
the objecti
on group:
4):643‐52.
3;53(3):139
‐89.
ó n B i o m
2 0 1 4 ‐ 2
tial relatio
me with bot
der energy‐
ple of RES
andomized
ugh two di
d for weigh
d and anth
nd oxidative
on (n=96). T
A methylati
ves propos
‐44.
é d i c a
0 1 5
nships bet
th adiposity
‐restriction.
SMENA pr
controlled
ietary strat
ht loss dur
hropometric
e stress mar
The studen
ion study as
sed. This wo
ween
y and
.
roject
trial,
tegies
ing 6
c and
rkers)
nt will
s well
ork is
PROJ
Gluco
obes
DEPA
Cent
(Edif
DIRE
Co‐d
CONT
plost
pgon
SUM
Back
been
impli
type
desc
meta
Our
oocy
meth
M á s t e
R e s
JECT 44
ose transpo
sity.
ARTAMENT/
re for Nutr
f. de Investig
CTOR
irectores: P
TACT
nmun@unav
MMARY
kground: Hy
n demonstra
icated in th
II diabetes
ribed that
abolism, wh
research: P
ytes express
hylglucose,
e r U n i v e
e a r c h P
orter GLUT‐
/LABORATO
rition Resea
gación), Sch
Prof. Pilar Lo
es; +349484
v.es; +3494
ypoxia is clo
ated that a
e developm
s as a resu
over‐expre
hich is chara
Preliminary
sing the tr
a specific su
e r s i t a r i o
r o j e c t P
‐12: study
ORY
arch/ Depar
hool of Phar
ostao y Dr. P
425600 ext
48425600 ex
sely related
lteration on
ment of thes
lt of insulin
ession of G
acteristic of
y studies fr
ansporter h
ubstrate of
o e n I n v e
r o p o s a l
of its physi
rtment of N
rmacy
Pedro Gonz
806228
xt 806650
d to obesity
n the expre
se diseases.
n resistanc
GLUT‐12 pl
f hypoxic ca
om our lab
have demo
the sodium
e s t i g a c i
E d i t i o n
iological ro
Nutrition, Fo
zález Munie
y, cancer an
ession of GL
. For examp
e. In this s
ays a dete
ncer cells.
boratory pe
onstrated t
m‐dependen
ó n B i o m
2 0 1 4 ‐ 2
le in hypox
ood Science
esa
d type II dia
LUTs transp
ple, GLUT‐4
sense, it ha
erminant ro
erformed in
hat GLUT‐1
nt glucose co
é d i c a
0 1 5
xia associat
e and Physi
abetes and
orters is di
activity is l
as been rec
ole in glyc
n Xenopus
12 transpor
otransporte
ed to
ology
it has
rectly
ost in
cently
olytic
laevis
rts α‐
er
SGLT
the p
nove
chara
Obje
poss
(real
obes
Refe
1. Th
like
Phys
2. Ex
Pujo
Dis. 2
POSS
YES
M á s t e
R e s
T1 but not o
presence of
el data th
acteristics d
ective and m
ible role of
time‐PCR, w
se animals m
rences
he facilitativ
to know?
iolBiochem
xpression o
l‐Gimenez J
2014 May 1
SIBILITY OF
e r U n i v e
e a r c h P
of the GLUT
f Na+ and t
at suggest
different fro
methodolog
f GLUT‐12 i
western blo
models.
ve glucose t
Pujol‐Gimé
m. 2013 Jun;
of the Gluc
J, Martisova
12
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
Ts. In additio
that sugar
t that GLU
om GLUT‐4.
gy: Therefo
n de develo
ot), in hum
transporter
nez J, Bar
69(2):325‐3
cose Transp
a E, Perez‐M
/NO)
o e n I n v e
r o p o s a l
on, we have
induces ele
UT‐12 is a
ore, the goa
opment of
man adipocy
r GLUT12: w
rrenetxe J,
33.
porter GLU
Mediavilla A
e s t i g a c i
E d i t i o n
e shown tha
ectric curre
a transpor
al of the p
obesity by
ytes under
what do we
, González‐
UT12 in Alz
A, Lostao MP
ó n B i o m
2 0 1 4 ‐ 2
at sugar upt
nts by GLU
rter with
roject is to
determinin
hypoxic co
e know and
‐Muniesa
heimer's D
P, Ramirez
é d i c a
0 1 5
take increas
UT‐12. Thes
new funct
o investigat
ng its expre
onditions a
what wou
P, Lostao
Disease Pat
MJ. J Alzhe
ses in
e are
tional
e the
ession
nd in
ld we
MP.J
ients.
imers
PROJ
Phys
DEPA
Labo
CUN,
Cent
DIRE
M.Pi
CONT
plost
SUM
Shor
goals
than
Back
brea
sensi
It ha
role
adipo
M á s t e
R e s
JECT 45
iological ro
ARTAMENT/
oratory whe
, CIMA etc.
re for Nutri
CTOR
lar Lostao C
TACT
MMARY
t summary
s and the m
three).
kground. Th
st cancer ce
itive tissues
as been rec
in glycolyt
ose tissue in
e r U n i v e
e a r c h P
le of the glu
/LABORATO
ere the proj
ition Resear
Crespo
es
of the proj
methodolog
e human fa
ell line MCF
s such as sk
cently descr
tic metabo
n obese ind
e r s i t a r i o
r o j e c t P
ucose trans
ORY
ect will be
rch/ Dept. N
ject with a
gy that will
acilitative gl
F‐7. In huma
keletal musc
ribed that o
lism, which
dividuals. W
o e n I n v e
r o p o s a l
porter GLU
carried out
Nutrition, Fo
maximum
be used.
lucose tran
ans, GLUT12
cle and adip
over‐expres
h is charac
We have dem
e s t i g a c i
E d i t i o n
T12 in the s
t indicating
ood Science
extension o
References
sporter GLU
2 protein is
pose tissue,
ssion of GL
cteristic of
monstrated
ó n B i o m
2 0 1 4 ‐ 2
small intest
Departmen
e and Physio
of 250 word
could be a
UT12 was is
expressed
, but also in
UT‐12 plays
hypoxic c
in heterolog
é d i c a
0 1 5
tine
nt, Area, Fa
ology
ds, includin
added (no
solated from
mainly in in
n small inte
ys a determ
cancer cells
gous expre
culty,
ng the
more
m the
nsulin
stine.
minant
s and
ssion
syste
and
resea
trans
abou
Goal
phys
gluco
studi
norm
POSS
Indic
Yes
M á s t e
R e s
em that GL
that sugar
arch has fo
sporter and
ut its role in
s and Me
iological ro
ose, and α‐
ies will be
mal rats and
SIBILITY OF
cate if the p
e r U n i v e
e a r c h P
UT12 is ab
uptake is
ocused on t
d its role on
the small i
ethos. Thus
le of GLUT1
methyl‐gluc
performed
d obese mod
Ph.D. (YES/
roject could
e r s i t a r i o
r o j e c t P
le to transp
increased
the study o
impaired i
ntestine.
s, the goa
12 in the sm
cose transp
using Caco
dels rats an
/NO)
d be continu
o e n I n v e
r o p o s a l
port α‐met
in the pres
of GLUT12
nsulin signa
al of the
mall intestin
port by func
o‐2 cells, a
d mice.
ued with a
e s t i g a c i
E d i t i o n
thyl‐glucose
sence of N
role as a
alling patho
present w
ne by studyi
ctional and
a human in
Ph. D. (doct
ó n B i o m
2 0 1 4 ‐ 2
e, a specific
Na+. During
secondary
ologies, but
ork is to
ing its locat
biochemica
testinal ep
toral thesis)
é d i c a
0 1 5
c SGLT subs
the past y
insulin sen
nothing is
investigate
tion, respon
al methods
pithelial cell
)
strate
years,
nsitive
know
e the
nse to
s. The
l line,
PROJ
Study
DEPA
Depa
DIRE
Dra.
Dra.
CONT
azun
SUM
Bruc
the d
deva
econ
Orga
and t
not p
Bruc
meta
infec
M á s t e
R e s
JECT 46
y of Brucell
ARTAMENT/
artment of M
CTOR
Amaia Zúñi
Maite Iriart
TACT
MMARY
ellosis is an
disease is t
astating effe
nomic losses
anization am
thus it is cr
provide abs
ella are fa
abolism to
ctious cycle.
e r U n i v e
e a r c h P
a central ca
/LABORATO
Microbiolog
iga Ripa
te Cilveti
es ;miria
n infectious
transmitted
ects. Abort
s and huma
mong the p
rucial to red
olute immu
acultative i
the extra
. Previous w
e r s i t a r i o
r o j e c t P
arbon meta
ORY
gy and Para
disease wh
d to human
ion and inf
an suffering
principal "fo
duce the in
unity, are un
ntracellular
and intra
work in our
o e n I n v e
r o p o s a l
bolism
asitology
es
ich affects
ns. Human
fertility in
g and Bruce
orgotten zo
fection in l
nstable and
r parasites,
acellular en
laboratory
e s t i g a c i
E d i t i o n
livestock an
brucellosis
infected an
ellosis is clas
onoses". Th
ivestock. Av
d interfere w
, and thus
nvironments
focused in t
ó n B i o m
2 0 1 4 ‐ 2
nd wild anim
s, if not tre
nimals is a
ssified by th
here is not
vailable ani
with diagnos
are able
s encounte
the central
é d i c a
0 1 5
mals, from w
eated, can
cause of m
he World H
human vac
imal vaccin
sis.
to adjust
ered during
pathways o
which
have
major
Health
ccine,
es do
their
g the
of
carbo
phos
More
curre
gene
is ne
new
The
bacte
codin
techn
these
POSS
Yes
M á s t e
R e s
on metabo
sphate dikin
eover, we
ently under
e is inactivat
cessary for
vaccines ag
project se
erial intrace
ng relevant
niques and
e mutants.
SIBILITY OF
e r U n i v e
e a r c h P
lism of Bruc
nase (ppdK)
have show
r investigati
ted. These r
understand
gainst bruce
eeks to fur
ellular mult
in vivo met
; (iii), propo
Ph.D. (YES/
e r s i t a r i o
r o j e c t P
cella abortu
and the m
wn that cla
on can imp
results show
ding Brucell
ellosis.
rther invest
tiplication.
tabolic enzy
ose vaccine
/NO)
o e n I n v e
r o p o s a l
us have sho
malic enzyme
assical Bru
prove their
w that a cor
la virulence
tigate Bruc
The specifi
ymes; (ii), g
es on the b
e s t i g a c i
E d i t i o n
own that ge
e (mae) are
cella vacci
immunizati
rrect knowl
e and could
cella metab
c objective
enerate mu
basis of the
ó n B i o m
2 0 1 4 ‐ 2
enes encodi
e required f
nes and o
on compete
edge of car
lead to the
bolic pathw
s are to: (i)
utants via m
in vivo cha
é d i c a
0 1 5
ing the pyr
for full virul
other candi
ence if the
rbon metab
developme
ways that
), identify g
molecular bi
aracterizati
uvate
ence.
dates
ppdK
olism
ent of
allow
genes
ology
on of
PROJ
Rem
DEPA
Depa
DIRE
Raqu
Ignac
CONT
rcond
imor
SUM
The
impo
bacte
and,
intra
of b
impli
cont
Bruce
M á s t e
R e s
JECT 47 (AS
odeling of B
ARTAMENT/
artamento d
CTOR
uel Conde‐Á
cio Moriyón
TACT
riyon@unav
MMARY
members o
ortant disea
eria trigger
accordingly
cellular nic
rucellae ar
icated in th
ribute.
ella e
e r U n i v e
e a r c h P
IGNADO)
Brucella me
/LABORATO
de Microbio
Álvarez
n Uría
es (ext 80‐33
v.es (ext 80‐
of the genu
ase affectin
r only low p
y, they follo
hes before
e of critica
hese prope
envelopes
e r s i t a r i o
r o j e c t P
embrane lip
ORY
ología y Par
393)
‐6356)
s Brucella a
ng livestock
proinflamm
ow a stealt
effective im
al importan
rties and t
conta
o e n I n v e
r o p o s a l
ids
asitología (
are α‐2 Pro
k and wild
matory respo
hy behavio
mmunity ac
nce in this
here is evid
ain p
e s t i g a c i
E d i t i o n
Universidad
oteobacteria
life as we
onses in th
or that allow
ctivation. T
strategy. T
dence that
hosphatidy
ó n B i o m
2 0 1 4 ‐ 2
d de Navarr
a that cause
ll as huma
e initial sta
ws them to
he outer m
The Brucell
other lipid
lglycerol,
é d i c a
0 1 5
ra)
e brucellos
n beings. T
ages of infe
reach shel
membranes
la LPS is c
d molecules
cardio
is, an
These
ection
tered
(OM)
learly
s also
olipin,
phos
ornit
with
catio
stres
1) To
2) To
polyc
POSS
M á s t e
R e s
sphatidyleth
thine lipids.
cationic a
onic antimic
sses. The go
o identify ne
o study the
cations or a
SIBILITY OF
e r U n i v e
e a r c h P
hanolamine
. In some b
aminoacyl
crobial pept
oals of this p
ew pathway
e role of th
acidic stress
Ph.D. (YES)
e r s i t a r i o
r o j e c t P
e, phosphati
bacteria, ph
residues. T
tides and is
project are:
ys of amino
he aminolip
es that Bruc
o e n I n v e
r o p o s a l
idylcholine
hosphatidylg
This simple
s also invol
acid conta
pids in the
cella faces d
e s t i g a c i
E d i t i o n
and amino
glycerol and
e modificat
ved in resis
ining lipids
OM stabilit
during its in
ó n B i o m
2 0 1 4 ‐ 2
acid‐contai
d cardiolipi
tion decrea
stance to o
synthesis in
ty and in th
ntra and ext
é d i c a
0 1 5
ining lipids
n are deco
ases bindin
osmotic or a
n Brucella.
he resistan
tracellular l
such
rated
ng of
acidic
ce to
ife.
PROJ
M á s t e
R e s
JECT 48
e r U n i v e
e a r c h P
e r s i t a r i o
r o j e c t P
o e n I n v e
r o p o s a l
e s t i g a c i
E d i t i o n
ó n B i o m
2 0 1 4 ‐ 2
é d i c a
0 1 5
M á s t e
R e s
e r U n i v e
e a r c h P
e r s i t a r i o
r o j e c t P
o e n I n v e
r o p o s a l
e s t i g a c i
E d i t i o n
ó n B i o m
2 0 1 4 ‐ 2
é d i c a
0 1 5
M á s t e r U n i v e r s i t a r i o e n I n v e s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t P r o p o s a l E d i t i o n 2 0 1 4 ‐ 2 0 1 5
PROJECT 49 Título: Estudio del mecanismo de acción leishmanicida de nuevos derivados selenados
Dirección: Esther Moreno Amatria y Carmen Sanmartín
Resumen:
La leishmaniasis es una patología que afecta a 12 millones de personas anualmente y 350
millones están en riesgo de infección. Los tratamientos farmacológicos disponibles
tienen serias dificultades por su baja eficacia, alta toxicidad y la aparición de cepas
resistentes. Por ello, hay una urgente necesidad de búsqueda de tratamientos
alternativos y eficaces. En los últimos años los derivados selenados están adquiriendo
relevancia por su implicación en nuevos mecanismos de acción basados en la
interferencia con los sistemas redox del parásito. Para este proyecto máster se propone
la profundización biológica en el estudio del mecanismo de acción de nuevos
compuestos que contienen selenio en su estructura y que han demostrado eficacia in
vitro frente al modelo amastigote de L. infantum así como una alta selectividad frente a
células tumorales lo que refrenda su potencial aplicabilidad terapéutica. Estos estudios
implicarán el análisis de la inhibición de enzimas redox (tripanotion‐reductasa, glutatión
peroxidasa, superóxido dismutasa etc) y en función de los resultados obtenidos análisis
en modelos in vivo.
M á s t e r U n i v e r s i t a r i o e n I n v e s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t P r o p o s a l E d i t i o n 2 0 1 4 ‐ 2 0 1 5
PROJECT 50
TITLE
Estudio del significado clínico pronóstico y predictivo del estado de metilación de la
enzima metil‐guanil‐metil‐transferasa (MGMT) valorado mediante técnica de
pirosecuenciación. Relación de dicha alteración con la mutación de la enzima isocitrato
deshidrogenasa (IDH).
DEPARTAMENT/LABORATORY
Neuropathology Unit. Department of Pathology. University Hospital and Faculty of
Medicine.
DIRECTOR
Miguel Idoate MD, PhD
CONTACT
[email protected] Phone number: 948296496‐ext.1163.
SUMMARY
Los gliomas son los tumores primarios más frecuentes del sistema nervioso central. De
ellos los glioblastomas son los tumores malignos más frecuentes. Existe en la actualidad
una intensa investigación en la búsqueda de nuevos biomarcadores pronósticos y
predictivos. La enzima metil‐guanil metil‐transferasa (MGMT) es uno de dichos
marcadores, que ha sido objeto de intensa investigación. El estado de hipermetilación de
DNA del gen de dicha enzima MGMT es un importante indicador de respuesta a los
agentes alquilantes como la temozolamida (Temodal). De tal manera, que si el promotor
del gen está hipermetilado es previsible que el fármaco sea efectivo. En la actualidad la
valoración del estado de metilación del gen de la enzima MGMT se lleva a cabo
mediante la técnica de PCR específica de metilación (PCR‐MSP). Sin embargo, esta
técnica no es suficientemente sensible para detectar la metilación cuando dicha
metilación sigue un patrón heterogéneo.
M á s t e r U n i v e r s i t a r i o e n I n v e s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t P r o p o s a l E d i t i o n 2 0 1 4 ‐ 2 0 1 5
Por otra parte, la interpretación de los resultados obtenidos con esta técnica adolecen
de subjetividad. Recientemente se ha propuesto la técnica de pirosecuenciación de la
MGMT como una buena alternativa a la detección convencional. En los estudios
comparativos entre ambas técnicas se ha observado que hasta un 24% de los
glioblastomas con metilación significativa detectada con la técnica de pirosecuenciación
no son detectados por la técnica de PCR‐MSP. Además, la técnica de pirosecuenciación
permite la cuantificación del grado de metilación de la enzima, que no es posible con la
técnica convencional. Dada la relevancia de la MGMT, es muy interesante el conocer el
poder pronóstico y predicitivo del status de la MGMT mediante pirosecuenciación, Los
resultados (numéricos) de este biomarcador (MGMT pirosecuenciada) lo
correlacionaremos con otros dos factores moleculares muy novedosos, considerados
clínicamente relevantes, como son la mutación del gen de la enzima
isocitratodeshidrogenasa (IDH1) y el grado de deleción del gen PTEN valorado mediante
técnica de LOH y uso de seis microsatélites.
MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial
tumors with IDH1 or IDH2 mutations.
Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT,
Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K.
Int J Cancer. 2012 Sep 1;131(5):1104‐13. doi: 10.1002/ijc.26499. Epub 2012 Jan 11.
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K,
Hoang‐Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.
Neuro Oncol. 2011 Jan;13(1):84‐98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, Wiemels JL,
Nelson HH, Karagas MR, Wrensch MR, Kelsey KT, Wiencke JK.
J Natl Cancer Inst. 2011 Jan 19;103(2):143‐53. doi: 10.1093/jnci/djq497. Epub 2010 Dec
16
M á s t e r U n i v e r s i t a r i o e n I n v e s t i g a c i ó n B i o m é d i c a
R e s e a r c h P r o j e c t P r o p o s a l E d i t i o n 2 0 1 4 ‐ 2 0 1 5
POSSIBILITY OF Ph.D. (YES/NO)
The project could be continued with a Ph.D.